annual report p e n n n v n p r n e r introduced ocrevus medicine people autism collaboration partners treatment two forms multiple spectrum disorder phase iii authorities developing sclerosis ocrevus demonstrated studies common nextgeneration diagnostic tests superior efficacy reducing neurodevelopmental condition medicines aim relapses slowing worsening characterised difficulties diagnosing treating multi disability caused ms regarding social interaction drugresistant bacterial infections contents overview strategy chairmans shareholder letter ceos shareholder letter business performance group performance diagnostics performance pharmaceuticals performance science innovation identifying medical need developing diagnostic tests health apps access healthcare joining forces make difference enabling sustainable healthcare funding people learning leadership development worldclass talent shaping future environment reducing energy water consumption reducing emissions air water community engagement strengthening local communities partnering make difference integrity business ensuring business continuity developing lasting partnerships corporate governance board directors corporate executive committee remuneration report principles remuneration components w ho innovation dna always worked across disciplines geographies drive scientific discovery redefine possible improve patients lives working understanding diseases also world leader vitro diagnostics differ molecular level business track record allows us build lasting develop new tests medicines prevent meaningful partnerships across world diagnose treat diseases bring research academia public healthcare institutions patients need combined strengths diagnostics pharmaceuticals founding families continue hold majority personalised healthcare strategy aims fit voting stake company stability allows right treatment right patient tradition sustainable thinking learn setbacks focus lasting value patients worlds largest biotech company develop society remain dedicated highest breakthrough medicines improving standard standards quality safety integrity legacy care across oncology immunology infectious based respect individual well diseases ophthalmology neuroscience communities world live inroches global presence employees worldwide europe employees north america basel kaiseraugst rotkreuz switzerland employees mannheim penzberg germany genentech south san francisco us roche diagnostics indianapolis us asia employees chugai tokyo japan shanghai suzhou china latin america employees africa australianew zealand employees employees research development sites pharmaceuticals manufacturing sites pharmaceuticals diagnostics worldwide diagnostics worldwide roche group headquarters manufacturing sites pharmaceuticals diagnostics largest sites based number employees sales sites pharmaceuticals diagnostics research development sites pharmaceuticals diagnostics number employees expressed fulltime equivalentshighlights managing multiple sclerosis testing infectious diseases ocrevus successfully launched treatment two forms portfolio cobas liat system tests extended fast multiple sclerosis debilitating disease diagnosis help control spread infectious diseases read read treating rare blood disorder improving access healthcare hemlibra approved treatment people haemophilia reimbursement four roche medicines china factor viii inhibitors blood disorder making available entire population read read progress cancer immunotherapy contributing sustainability results number tecentriq clinical studies date roche ranked sustainable healthcare company demonstrate significant medical benefit dow jones sustainability indices ninth year running read read key figures chf million chf million group sales r core investments chf million roche medicines core operating profit model list essential medicines chf million patients dividend treated roche medicines growth rates report constant exchange rates cer average por ting approach roche committed transparent reporting endeavour drive economic social environmental performance diligence financial performance reporting scope boundaries business sustainability risks opportunities provide integrated information financial annual basis integrate existing online annual nonfinancial performance annual report risk management process report finance report well online report arrochecom cover regions divisions january consolidated group risk report covers december reporting scope defined material risks discussed annually roche annual outlined finance report corporate executive committee reviewed report pdf significant changes scope compared audit committee board directors wwwrochecom board directors effectiveness arepdf reporting accordance latest risk management process regularly monitored gri guidelines group risk advisory team overall roche finance followed gri g guidelines global process reviewed externally appropriate risk report pdf reporting initiative since using gri management embedded levels group wwwrochecom guidelines disclose critical impacts pharmaceuticals diagnostics divisions fbepdf activities environment society economy global functions conduct formal risk assessment reporting period transitioned process least year must develop risk risk management newly introduced gri standards based plans material risks rochecomrisk key concepts disclosures gri g management guidelines report accordance standards group risk advisory facilitates risk discussions core level also go beyond requirements support business many specialist areas core level number indicators security well compliance sustainability training sessions platforms established risk management help employees manage monitor mitigate risk management policy sets roches approach risks appropriately identifying managing reporting internal external risks opportunities also identify read corporate governance reporting approach roche material topics external assurance tier fundamental drivers ability deliver current annual report includes independent core purpose long term assurance report nonfinancial reporting prepared pricewaterhousecoopers ag rd pipeline strategy personalised healthcare employee engagement talent retention see independent assurance report growth strategy emerging developed markets product portfolio strategy materiality patent policies accordance gri standards conducted leadership commitments first materiality analysis corporate level gathered input feedback various internal external sources conferences tier major influencing factors business conducting regular interviews oneonone success short medium term discussions key stakeholders results since regularly vetted ongoing stakeholder pricing research across key markets stakeholder groups disease awareness treatment education enables us include topics stakeholder compliance groups consider important business drug efficacy safety counterfeiting healthcare sector patient organisations supply chain management physicians laboratory staff employees media biosimilar safety investors payers regulators governments sustainable healthcare material topics screened priorities deemed key roche three tiersfirstly fundamental drivers ability deliver core purpose tier additional material topics long term secondly additional annually reviewed major influencing factors business success executive remuneration materiality short medium term finally compensationbenefits rochecom material topics providing three levels priority organisational effectiveness materiality addressing material topics environmental responsibility community engagement key performance three tiers material topics reflected patient organisation support indicators business priorities report content highlighted data transparency clinical trials rochecom beginning chapter well aspect occupational accidents performance boundaries according gri build concrete actions relating topics operational activities measure performance defined indicators see strategy approach su stainability sustainability means us alignment individuals goals interests society preserving natural resources ultimately helps meet goals acting sustainably contribution un sdgs contribute positively towards development world rochecomunsdgssdgs roche committed sustainability many years contribute number united nations sustainable development goals sdgs innovating patients million patients treated roche medicines supporting billion tests conducted roche diagnostics products sdg roche medicines model list essential medicines trustworthy partner new partnerships diagnostics supporting new partnerships pharmaceuticals sdgs approximately businesscritical suppliers riskassessed protecting environment decrease water consumption since supporting decrease energy consumption since sdgs improvement ecobalance since delivering continued growth group sales supporting core operating profit sdgs sustainability leader within pharmaceuticals biotechnology life sciences industry index per djsi providing great workplace employee engagement rate supporting women key leadership positions sdgs key leaders diverse work experience world health organization growth rates report constant exchange rates cer average focus people fitting treatments patients making mark distinctiveness decisionmaking excellence science accountable transparent delivery structure value stakeholders built innovation itour strategy roche strateg focus finding new medicines diagnostics help patients live longer better lives evolve practice medicine guided purpose deep understanding molecular biology seamless patients need next company integration pharmaceuticals diagnostics year history advancing field medicine capabilities diversity approaches maximise bringing novel treatments diagnostics patients innovation longterm orientation patient remain core reason come work every day delivery create value stakeholders partner choice bringing significant medical benefit patients doctors payers offering great place work employees sustainable impact society creating topquartile total focus fitting treatments patients providing shareholder return investors right therapy responding group people right time inhouse combination pharmaceuticals diagnostics uniquely positioned deliver personalised healthcare developing internal capabilities building strategic end takes people integrity courage partnerships ready next stage personalised passion make difference patients people healthcare combine insights multiple data proud say roche embrace sources sophisticated analytics drive diversity cultures people across group effective efficient research allow better inclusive encourage richness ideas therapeutic decisions patients access products approaches brings also critical part strategy detailed access plans embedded business local level decisionmaking principles processes emphasise transparent dialogue clear accountability continue concentrate energies entirely encourage high degree empowerment prescription medicines vitro diagnostics rather diversify sectors like generics structure built innovation autonomous biosimilars overthecounter medicines research development centres alliances medical devices external partners foster diversity agility global geographical scale reach enables us pursuit excellence science distinctiveness bring diagnostics medicines quickly people rests four key elements exceptionally broad need mark et e nv ironme nt digital technology transforming healthcare trials simple patients investigating doctors ongoing digital revolution driving radical participate minimising inconvenience transformation healthcare bringing solutions time effort entailed improving research development patient involvement care outcomes costefficiency demand digital developments making possible medical care continuing grow transformation decentralising clinical studies clinic hospital urgently needed economic sustainability patients home many doctorpatient interactions global healthcare expenditure projected reach take place virtually telemedicineenabled usd trillion usd trillion contact supported digital diagnostic tracking placing pressure healthcare systems tools facilitate physical examinations distance patients increase access key developments technologysuch internet clinical studies significantly reduce travelling things machine learning robotics deep waiting times well inconvenience dataare enabling enormous progress healthcare technology applying sophisticated analytics piloting cuttingedge clinical study designs personalised healthcare result treatment strategies feature continual evaluation array unprecedented precision becoming reality data fed back refine study better identify potential drug combinations overall proper application developments activities allow us develop bring right safe help us find solutions complex challenges medicine patient efficient manner face move us towards patientcentred outcomesbased care whilst making efficient use improving treatment outcomes resources solutions bring wideranging improvements diagnostics possibilities targeted benefits complex individual treatment strategies therapies combinations medicines offer wide improved chronic care management range treatment choices complexity require clinical decision support tools innovationfocused company forefront driving developments diagnostics deep data helping take personalised healthcare pharmaceuticals see digital revolution new level roche partnering companies major impact four key areas flatiron health foundation medicine inc fmi ge healthcare help us better leverage data transforming clinical studies advanced analytics improve development roche conducted clinical trials medicines decisionmaking patient care patients involved want make first data new bloodbased assay measuringmarket environment roche experts developed industryleading platform uses cuttingedge imaging science look inside tumour document effect new drug candidates patients complex data generated digitised interpreted drive better decisions drug development tumour mutational burden codeveloped fmi enabling patient empowerment improve understanding immune biology technology empowers patients giving ultimately help match therapies control health example enabling combinations people likely benefit selfmanagement providing information connecting patients monitoring enhancing treatment modern diagnostic tools including pointofcare adherence testing connectivity data remote monitoring disease potential improve treatment health apps sensors digital biomarkers provide outcomes disease management early rich source information data tracking detection example online platform digital well improved convenience example roche diabetes management helps healthcare providers developed app continuously measure symptom make better faster therapy decisions also fluctuations parkinsons disease patients without improving communication patients roche needing visit clinic also launched navify tumor board solution clinical workflow decision support software future individuals better informed optimises decisionmaking cancer patient case genetic profile diseases reviews clinic socalled tumour boards availability appropriate therapies match multidisciplinary team meetings specific condition economist intelligence unit world industry outlook healthcare pharmaceuticals june european society medical oncology congress september madrid spain efficiency technology enabling timely accurate diagnosis treatment improved success rates also minimising unnecessary treatment resulting significant efficiency gains usage resources available optimised addition roche utilising digital technologywhether revamp conduct clinical trials use data change register new productsto become much efficient roches efforts digitisation part continued commitment furthering benefits products services bring patients go hand hand work currently ongoing trying better understand science interpret data quicker use new technologies end goal bringing innovative treatments right patient faster business model innovation ensure continue providing innovative products services patients invest onefifth sales research development rd activities every year thanks focus science areas high unmet need expertise pharmaceuticals diagnostics one roof successful introducing six new medicines different diseases indications navify tumor board software supports decisionmaking optimise therapy patients many new diagnostic tests instruments cancer services since late additionally broad exciting pipelines pharmaceuticals diagnostics divisions investing today bring hope tomorrow focus therapeutic areas make significant contributions society includes disorders central nervous system alzheimers disease autism aremarket environment roche roche developing new medicines conducting studies need high level investment diagnostics advancing vision diseases seen major integrated core laboratory broad range diagnostic tests fully automated processes progress decades roche also innovating areas unmet need developing new medicines diseases major progress decades including medicines generics biosimilars supports bladder cancer tecentriq multiple sclerosis ocrevus financial sustainability healthcare systems giant cell arteritis actemraroactemra approved fda november hemlibra offers immense total drugs included potential improved quality life model list essential medicines haemophilia pointofcare cobas liat system roche medicines widely available tests provide precise test results rapidly time benefit large number people billion essence patients survival people treated roche antibiotic bactrim since introduction example value innovation many patients treated generic major advances science data technology versions similarly foundational polymerase chain aiding development increasingly sophisticated reaction pcr technologies developed roche treatment options diseases like cancer efficient way copy amplify small segments immunotherapies combination therapies real dna rnastill benefit millions people value innovation realised actually even though patents expired reaches benefits patients need roche actively working payers governments regulators across globe implementing develop flexible pricing solutions facilitate flexible procedures review approve public reimbursement well assistance programmes truly innovative medicines faster breakthrough help patients access treatment therapy designations us prime eu significantly reduce lead time lifesaving patents protect intellectual property allow drugs also helps roche recover investments product portfolio commercial exclusivity faster enables investment additional limited period time recover investments areas including studies rare diseases research development benefit spinal muscular atrophy erdheimchester disease necessary innovation premium business enterprise however patent medicine expires innovation generate value developing innovation represents continues benefit society products advance standard care diseases biosimilars generics may become available lower significant unmet need able meet costs increase number patients obligations shareholders society treated open competition originator whole number december prime priority medicines scheme launched european medicines agency ema enhance support development medicines target unmet medical need ear shareholders despite rapid medical scientific advances treatment individual patient shortest still cures common illnesses possible time alzheimers disease million people world access basic healthcare infectious remarkable progress divisions attributable diseases believed eliminated least fact chf billion proving resistant treatment invested research development backdrop must also measure success healthcare company strength business year terms extent find innovation also reflected good financial results solutions urgent medical problems sales chf billion core operating profit chf billion decrease net income past year made significant accordance ifrs due extraordinary items progress drug development roche received amortisation impairment breakthrough therapy designations medicines new compounds times recent years four yet efforts vain products fail designation offers prospect reach people need working faster approval awarded us health years improve access healthcare throughout authority fda initial clinical trial data exhibit world become abundantly clear promising efficacy serious diseases roche leads dialogue cooperation involved industry terms indicator innovative affected bring lasting improvements also strength important systematically address limiting factors inadequate infrastructure given rapid pace data volumes education lack disease awareness one growing digital decisionmaking tools becoming significant problem often lack basic health increasingly important medical practice insurance jointly partners therefore consequence roche diagnostics ge healthcare extended introduction private insurance recently entered longterm strategic partnership policies cancer treatment china focussed developing comprehensive digital asian countries time working platformsinitially oncology intensive care supervisory authorities governments medicinesto support doctors identifying best industry combat new threats antibioticchairmans shareholder letter roche become abundantly clear collaboration involved bring lasting improvements concerning access resistance development new types propose dividend increase swiss francs per diagnostic products medicines share nonvoting equity security annual general meeting subject approval many tasks require patience st consecutive dividend increase stamina sustainability long important component business strategy pursue offer thanks worked together integrated approach want us achieve medical advances constantly improve therapeutic standards improve access medical care thank employees also working improve access products tireless dedication past year chairmans video taking social responsibility crucial areas offer shareholders heartfelt thanks rochecommed environmental protection supply chain trust placed us corhtm employee retention delighted diverse sustainability efforts rewarded ninth consecutive yearwith top ranking dow jones sustainability indices whole look back successful year believe roche well positioned continue contributing medical solutions efficient dr christoph franz healthcare environment innovation chairman growth rates report constant exchange rates cer average board directors roche board directors bernard poussot c e dr christoph franz chairman c e dr severin schwan f prof dr richard p lifton c e julie brown b e dr claudia suessmuth dyckerhoff b e anita hauser e paul bulcke b e prof sir john bell b e dr andreas oeri representative shareholder group pooled voting rights e andr hoffmann vicechairman representative shareholder group pooled voting rights c e peter r voser c e corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson roche board directors december ear shareholders successful year rochein terms fdahas proven superior established treatment financial results certainly especially methods furthermore latest results important development new medicines diagnostic products trials pioneering field cancer immunotherapy great news looking back demonstrate potential tecentriq past year also solid basis us face treatment various types cancer future confidence laid groundwork drive forward delivery personalised healthcare immunology played significant role solutions thus actively help shape change growth diagnostics division healthcare sector expanded fully automated immunodiagnostics portfolio bringing us step closer integrated exceeded growth targets divisions core lab help central laboratories gratifying growth become efficient competitive pharmaceuticals division came new products ocrevus tecentriq alecensaand shows digitisation healthcare gives us opportunity consistently achieving goal renewing make faster progress area personalised portfolio regionally us experienced particularly healthcare analysis realworld dataanonymised strong pharmaceutical sales growth patient data visits doctors medical records diagnostics division sales showed especially sharp sourceswill give major boost rise china innovation medium long term diagnostic products alone billion tests especially pleased able conducted million patients introduce new products areas significant treated medicines last year medical need recent approval ocrevus took part clinical trials want example gives patients multiple sclerosis access make better use underlying wealth data effective treatment hemlibra innovative crossdivisional research development haemophilia treatment closes major gap activities requires close collaboration treatment serious blood disorder prevent healthcare providers health insurers authorities halt bleeds adults young people children continued expand partnerships recent trials hemlibragiven fasttrack approval throughout world past yearceos shareholder letter roche growth new products demonstrates consistently achieving goal renewing portfolio midst change one thing constant sales expected grow stable lowsingle importance employees company digit range constant exchange rates core earnings past year shown high degree flexibility per share targeted grow highsingle digit passion help shape future ninety percent constant exchange rates excluding us tax reform employees worldwide participated internal impact core earnings per share targeted grow employee survey eightytwo percent said broadly line sales roche expects proud work roche confirmation increase dividend swiss francs incentive continue efforts ceos video preferred employer attracting retaining best would like thank valued shareholders rochecommed talent industry trust placed company corhtm year transition long foreseen expect competition biosimilars cancer medicines mabtherarituxan herceptin mainly europe initially time however systematically renewing portfolio innovative products though challenges multiplying believe well positioned successfully overcome thanks dr severin schwan ongoing strength medical innovation chief executive officer growth rates report constant exchange rates cer average corporate executive committee roche corporate executive committee dr stephan feldhaus head group communications dr alan hippe chief financial officer osamu nagayama chairman ceo chugai dr gottlieb keller general counsel roland diggelmann ceo roche diagnostics cristina wilbur head group human resources daniel oday ceo roche pharmaceuticals dr michael varney head genentech research early development gred dr severin schwan ceo roche group dr sophie kornowskibonnet head roche partnering prof dr john c reed head roche pharma research early development pred member enlarged corporate executive committee roche corporate executive committee december business performance roche bu sine pe r mance three recently launched medicines contributed strongly growth topselling products show continued doubledigit sales increases material topics covered chapter product portfolio strategy growth strategy emerging developed markets contribution un sdgs g ood results divisions group sales rose chf billion solutions main contributor led core operating profit grew reflecting strong growth immunodiagnostics business underlying business performance core eps increased regional terms growth driven asiapacific ifrs basis net income decreased continued strong growth china ifrs result includes charges impairment sales increased europe middle east africa goodwill intangible assets amortisation emea latin america stable intangible assets north america sales pharmaceuticals division increased approvals line extensions pharmaceuticals chf billion recently launched medicines us fda approved two new medicines ocrevus tecentriq alecensa contributed namely ocrevus treatment relapsing chf billion new sales represents primary progressive forms multiple sclerosis divisions growth perjeta also continued strong hemlibra people haemophilia sales increase growth partially offset factor viii inhibitors lower sales tarceva avastin course year health authorities approved us sales advanced led ocrevus number new indications existing products tecentriq xolair mabtherarituxan europe december us fda approved perjeta sales declined mainly due lower mabthera combination herceptin chemotherapy rituxan sales driven competition biosimilars adjuvant surgery treatment herpositive international region sales grew led early breast cancer high risk recurrence latin america asiapacific subregions japan approval based results phase iii aphinity sales increased main growth driver study us approval granted alecensa alecensa anaplastic lymphoma kinase alkpositive non small cell lung cancer nsclc gazyva diagnostics division sales increased untreated advanced follicular lymphoma chf billion centralised point carebusiness performance roche development pipeline made good progress shown approvals new medicines line extensions positive results clinical studies key areas highlights include data studies cancer immunotherapy clearly reflect potential tecentriq treating different kinds cancer europe key approvals granted course connectivity automation laboratories year including alecensa monotherapy new instruments support efforts expand core firstline treatment well previously laboratory consolidate integrate wider range treated alkpositive advanced nsclc platforms covering diagnostic disciplines molecular diagnostics lab coagulation january ocrevus approved eu haematology pointofcare testing treatment relapsing primary progressive form multiple sclerosis chmp approach supported expanding recommended approval hemlibra existing broad test portfolio additional new tests include cobas liat system tests integrated diagnostic solutions rapid identification lifethreatening infectious course year five new key instruments diseases healthcareassociated infections methicillin launched allow increasing resistant bacteria viral infections growth rates report constant exchange rates cer average ales diagnostics division grew strongly chf billion centralised point care solutions hiv testing impacted lower sales hcv tests largest contributor divisions sales growth due base effect strong hcv test sales integrated serum work area solutions comprising immunodiagnostics clinical chemistry tissue diagnostics sales increased driven segments main growth drivers advanced staining primary staining portfolios grew respectively companion sales molecular diagnostics increased sales diagnostics business grew human papillomavirus hpv screening blood screening businesses grew diabetes care sales decreased affected challenging respectively virology sales stable growth market conditions particularly north america topselling product portfolios chf millions cobas cobas ventana cobas accuchek immunodiagnostics clinical chemistry advanced staining virology diabetes care business performance roche north america europe middle east africa emea japan latin america asiapacific divisions sales growth driven asiapacific region contributions regions varied due different levels market maturity increased access healthcare diagnostic economic development africa major healthcare solutions demographic shifts advances science access programmes implemented technology led globally increased demand number local governments close collaboration diagnostics leader field vitro international organisations diagnostics roche well positioned address unaids partners industry roche supports market dynamics however public funding constraints several initiatives sustainable commercial led consolidation laboratories hospitals offers overall diabetes care sales declined within resulting continued price pressure diagnostic region however growth seen several markets providers number people diabetes continues grow along awareness latin america business segments contributed condition need manage adequate growth sales expanding diabetes care blood glucose monitoring systems north america sales growth led tissue asiapacific region major driver diagnostics roche continues gain market share divisions growth immunochemistry key laboratory decentralised coagulation contributor china generated almost half absolute monitoring segments recently launched products sales growth markets within region continued important new business development see volume growth expanded access testing offset lower sales diabetes care business diabetes care sales also fell due continued price pressure sales increase emea region driven sales growth japan driven centralised core laboratory business contributions markets point care solutions diabetes care sales declined growth rates report constant exchange rates cer average diagnostics medical value improve health empowering laboratory leadership may cobas e module received fda developing new integrated diagnostic approval expands systems success markets solutions designed address challenges today already launched strengthens anticipate needs tomorrow key icl solutions cobas e module offers high expand core laboratory consolidating value flexibility designed high integrating wider range platforms covering throughput continuous operation diagnostic disciplines molecular diagnostics time reduces waste lab coagulation haematology pointofcare testing integrated core lab icl vastly expands also may launched avenio ctdna analysis efficiency scope quality diagnostic kits portfolio three nextgeneration sequencing capabilities laboratory ngs liquid biopsy kits oncology research kits detect four mutation classes high sensitivity january cobas new dedicated kits researchers profile genomic haematology testing solution became available complexities different cancer stages tumour countries accepting ce mark marked types obtaining results five days avenio entry haematology diagnostics market millisect system tissue dissection instrument cobas provides greater accuracy consistency utilising automated digitallyassisted process results identifying counting isolating reliably efficiently isolate clinically relevant cells categorising abnormal cells within patient samples testing became commercially available july automation digitisation reduces need resourceintensive manual microscope reviews diabetes care business aim enable better allows quicker delivery results ultimately management diabetes major healthcare burden aids patient diagnosis focus integrated diabetes management increased time range people diabetes acquisition mysugr gmbh austria june key roche integrated core lab vastly executing diabetes care strategy expands efficiency quality acquisition viewics inc us november allows roche expand leading position customers diagnostic capabilities icl business analytics capabilities enablingbusiness performance roche laboratories make faster datadriven informed decisions operations processes december entered strategic longterm partnership ge healthcare jointly develop comarket digital clinical decision support solutions partnership initially focus products accelerate improve personalised treatment decisions patients cancer critical care ge healthcare aim develop industryfirst digital platform allows seamless integration analysis patient records realtime data medical roche offers broad range tests womens health including areas fertility best practice latest research outcomes bone health cancer womens health improving access healthcare means women april received k clearance fda world benefit enhanced cintec histology test test disease prevention improved screening approaches clinically validated p biomarker test helps better diagnostic tests roche currently pathologists determine women receive offer comprehensive range tests covering fertility treatment cervical precancer test part pregnancy bone health breast cancer ovarian cervical cancer portfolio includes cancer cervical cancer february launched cobas hpv test cintec plus cytology test elecsys amh plus immunoassay first available ivd test us cintec cemarked companion test fertility therapy histology test performed benchmark ihc ish series instruments used confirm march launched ivd cobas hpv test presence absence highgrade cervical disease cervical cancer screening cobas women tissue biopsy using systems countries accepting ce mark p biomarker enables conclusive diagnosis hpv dna assay gives laboratories ability providing distinctive visual confirmation pre run hpv dna testing simultaneously cancerous cervical lesions may missed previously released cobas infectious disease assays hematoxylin eosin interpretation alone ce mark certification mark indicates conformity within eu wwwwhointmediacentrefactsheetsfsen infectious disease tests expanding broad portfolio infectious diseases represent serious growing infection life threatening global threat announced world people solid organ transplant develop running effective antibiotics fight increasingly symptomatic cmv infection cobas cmv test resistant bacteria ever highly efficient standardised first international standard automated tests provide accurate diagnostics improving harmonisation cmv testing results playing critical role preventing overuse across healthcare institutions addition cmv antibiotics helping health systems control assay cobas system comprehensive test spread infectious diseases menu including viral load assays hiv hcv hcv genotyping hbv april launched cobas liat system four infectious disease assays ce markets july cobas liat system menu expanded cobas liat system offers first realtime pcr ce launch cobas mrsasa test nucleic acid test detect clostridium difficile qualitative detection differentiation minutes timely accurate diagnosis methicillinresistant staphylococcus aureus mrsa infection vital one major causes staphylococcus aureus sa point care healthcareassociated infections hai quickly many million people carry mrsa one become life threatening especially highrisk patients commonly identified antibioticresistant elderly compromised immune pathogens europe patients systems undergoing antibiotic treatment develop mrsa infections year resulting cobas liat assay represents breakthrough patients million excess days hospitalisation since traditional diagnostic methods may take several eur million extra inhospital costs designed hours results delivered clinicians support rapid screening surveillance mrsa cobas liat cdiff assay part hai portfolio sa cobas liat system ideal use expands existing diagnostic menu available emergency settings intensive care units cobas liat system includes respiratory conventional testing methods may take assays cobas strep influenza ab rsv hours turn around culture results cobas liat system testing takes minutes june received approval cytomegalovirus used admission surgery reduce cmvviral load testing cobas system risk transmission within hospital also countries accepting ce mark transplant july launched first cemarked hivhiv patients cmv common serious viral qualitative tests use fully automatedbusiness performance roche cobas plasma separation card part global access programme helps expand access diagnostics countries hardest hit hiv underscores commitment providing lifesaving diagnostics fight hiv aids allows testing even areas transportation lab may take weeks cobas systems allowing healthcare first commercially available test detection professionals optimise treatment options zika virus rna samples human plasma intended use screening blood donations september announced plans immediately newly approved cobas zika test used initiate screening blood samples cobas alongside routine tests screening babesia test investigational new drug blood plasma donations us application protocol performed cobas systems test screens direct detection december roche launched cobas plasma babesia dna rna whole blood specimens separation card innovative technology easy individual blood donors commonly transmitted sample collection utilising gold standard humans bite infected tick plasma sample type small amount blood babesia parasite also transmitted blood collected specially designed cards blood collection transfusions mother foetus infects sample transportation simplified resource destroys red blood cells potentially leading anaemia limited settings first plasma related lifethreatening complications people separation card remaining stable extreme heat compromised immune systems humidity providing results correlate plasma viral load standard care meeting october fda approved cobas zika test decision requirements use cobas systems cobas zika test wwwwhointmediacentrenewsreleasesrunningoutantibioticsen kock r et al euro surveill business performance roche alan staple clinton health access initiative us partnership helped change worlds attitude towards viral load testing joining clinton health access initiative hiv status receive treatment chai nine years ago working executive people treatment virally suppressed contract research industry focus reduce time market new drugs prior launch programme better management trials demonstrate quarter patients lowerincome countries drug safety efficacy felt truly motivated access viral load testing number lives could saved cutting months even years development process started project viral load testing considered expensive complicated head global markets team infrastructure place transport chai addressing similar challenge process samples however assumptions work within global regulatory proven wrong production financial systems get highquality infrastructure cuttingedge technologies medicines diagnostics patients lowerincome countries affordable sustainable prices partnership roche helped change global footprint chai works partners like worlds attitude towards viral load testing roche companies worldwide reach developing world back transformative impact global collaboration well funders public health problems changed recom mendation previously werent recommending viral load testing successful longterm collaboration every patient collaboration roche area hiv goes back many years together pioneered early goal includes viral load testing infant diagnosis routine programme hiv diagnostics evolved something currently infants tested every wasnt even mentioned five years ago key year set global access programme measure programmes success result contributes unaids goal standard viral load testing place words people living countries like switzerland hiv know status people lowerincome countries well ales pharmaceuticals division increased chf billion largely driven growth recently launched medicines herceptin perjeta kadcyla combined us driven immunology international herpositive breast cancer herpositive region sales europe affected metastatic gastric cancer herceptin herceptin market entry biosimilars sales led growth us brazil perjeta sales grew regions following avastin advanced colorectal breast lung increased demand neoadjuvant metastatic kidney cervical ovarian cancer relapsed settings sales kadcyla increased glioblastoma type brain tumour us sales declined largely due increasing use cancer mabtherarituxan forms blood cancer immunotherapy medicines lung cancer sales rheumatoid arthritis certain types vasculitis continued grow international region sales continued rise increases recorded key growthdriving products chf millions mabtherarituxan herceptin perjeta actemraroactemra xolair oncology immunology oncology oncology immunology immunology business performance roche sales europe affected removal gazyvagazyvaro chronic lymphocytic reimbursement breast cancer france leukaemia cll rituximabrefractory follicular lymphoma previously untreated advanced actemraroactemra rheumatoid follicular lymphoma sales expanded regions arthritis forms juvenile idiopathic arthritis product launched giant cell arteritis sales growth reported regions supported steady growth demand recently launched medicines subcutaneous formulation ocrevus chf million approved countries experienced continued strong demand xolair us chronic idiopathic indications tecentriq chf million urticaria allergic asthma growth driven approved countries alecensa chf million demand indications approved countries showed good uptake us continued strong sales growth japan activasetnkase thrombolytic clotbusting november hemlibra chf million launched agent acute ischaemic stroke sales increase us promising uptake driven broader use hospitals higher number treated patients key growthdriving products chf millions activasetnkase kadcyla ocrevus tecentriq alecensa cardiovascular oncology immunology oncology oncology growth rates report constant exchange rates cer average applicable regional performance growth driven us brazil china us medicines demand foundation medicine us market continues area significant services increasing make service opportunity despite increasing complexity driven broadly available across europe seek take rising competitive pressure dynamic regulatory personalised cancer care next level region environment shift towards valuebased healthcare contributed overall pharmaceuticals models overall performance market business sales perjeta actemraroactemra characterised new product launches including remained robust regions performance ocrevus hemlibra received four impacted declining sales mabtherarituxan breakthrough therapy designations btds avastin due biosimilar competition means awarded total btds since reimbursement reduction respectively fda established programme addition fda also granted seven priority reviews japan fuelled strong sales new existing sales grew alecensa sales increased sales medicines us recorded growth tamiflu actemraroactemra accounts total pharmaceuticals business growth partially offset lower sales sales growth largely driven ocrevus tecentriq various established products chugai contributed xolair mabtherarituxan overall pharmaceuticals business europe international region working number stakeholders recent years latin america seen stable european national level develop solutions growth allowed governments spend ensure sustainable healthcare systems well healthcare however significant challenges timely equitable access innovative remain landscape marked barriers medicines together payers developing impede access healthcare including low levels implementing flexible pricing solutions disease symptoms awareness late diagnosis weak aimed supporting faster access innovative infrastructure inefficient insufficient funding delays adoption innovative medicines country latin america faces unique challenges fuelled strong sales us roches commitment varied region therefore partner various stakeholders growth driver division develop tailored solutions help increase access tobusiness performance roche europe eastern europe middle east africa eemea japan us latin america asiapacific eemea latin america asiapacific canada form international region medicines diagnostic tests latin america achieved strong results regions priorities include contributed overall pharmaceuticals improving access competing biosimilars business sales growth driven brazil noncomparable biologics preparing launches argentina innovative medicines achieved considerable success accelerating registration asiapacific region sales growth driven timelines medicines tecentriq established products strategic products new ocrevus becoming available patients several launches china herceptin mabtherarituxan countries even ema approval avastin tarceva listed national time markets experienced order shifts reimbursement drug list nrdl markets like russia iran lost government tenders significant step towards making medicines biologics negatively impacted regional available entire population billion people performance steady entry new medicines country several new medicines launched mitigating losses products face biosimilar region including ocrevus tecentriq competition strategic products contribute growth asiapacific region contributed overall perjeta kadcyla among topselling pharmaceuticals business growth primarily medicines region eemea markets driven china taiwan vietnam australia contributed pharmaceuticals business even challenges key markets impacting overall performance many countries eemea region additional options patients new products drive growth recently launched medicines ocrevus tecentriq alecensa first launched japan alecensa good start following approved treatment type lung cancer arrival multiple markets ocrevus treatment sales total chf million relapsing primary progressive forms multiple sclerosis rms ppms met extremely positive combined new medicines contributed response receiving approval us march chf billion new sales represents prescriptions continued increase throughout pharmaceuticals divisions growth driving overall year leading sales chf million growth offsetting decreasing sales products end people phased affected competition treated ocrevus globally continued strong sales increases tecentriq first approved several topselling products show treatment advanced bladder cancer us continued doubledigit sales growth example meantime tecentriq also approved perjeta representing major advance advanced lung cancer important new cancer treatment patients breast cancer generated immunotherapy treatment option contributed total sales chf billion contributed chf million sales roche conducting large chf million new sales first launched number studies tecentriq combination usage broadening study results medicines roches marketed investigational confirm medical benefits additional indications portfolios well external partners late fda approved perjeta combination effort improve treatment outcomes results herceptin chemotherapy adjuvant number clinical studies date demonstrate surgery treatment herpositive early breast significant medical benefit cancer high risk recurrence approval based results phase iii aphinity study actemraroactemra sales increased totalling chf billion xolair sold genentech ocrevus tecentriq alecensa us saw sales advance chf billion activasetnkase sales contributed divisions growth chf billionbusiness performance roche new medicines unmet needs three innovative medicinesactemraroactemra approval tecentriq treatment bladder alecensa hemlibraoriginate research cancer represents major advance people affected laboratories chugai japan member potentially lifethreatening disease roche group since brought major advances treatment type market collaborations experts across cancer last years entire roche group represent major contributions patients physicians society whole ocrevus highly effective treatment option people rms ppms offering favourable benefitrisk profile demonstrated three phase iii multiple sclerosis forced former taekwondo world champion amr khairy wheelchair studies despite available therapies people relapsing forms ms continue experience disease activity disability progressionworsening disability people ppms approved treatment previously experience faster accumulation disability ocrevus given every six months potential transform therapy forms ms approval actemraroactemra giant cell arteritis added list major break therapies diseases high unmet need actemra roactemra first new treatment option debilitating disease years hemlibra received fda approval november contributes roches strong history innovation transforms medical practice hemlibra bispecific monoclonal antibody designed restore blood clotting process people haemophilia factor viii inhibitors administered injection readytouse solution skin weekly clinical development programme looks potential help overcome current challenges shortlasting effects existing treatments development factor viii inhibitors need frequent infusionsbusiness performance roche dr amr khairy former taekwondo world champion egypt multiple sclerosis patients truly suffer lot initially interested sports like tennis therapy would beneficial used really good even took part travel around globe participate national tennis championships squash taekwondo tournaments football finally took taekwondo search treatment attack seriously time continuing couldnt move talk used paralysed studies accepted faculty medicine couldnt even swat fly cairo father surgeon wanted reward trip america instead asked finally underwent experimental stem cell send korea improve taekwondo skills treatment china trained physician first olympics seoul understood risks decided proceed went barcelona gold treatment therapy left confined various world championships diagnosed wheelchair yet almost attacks multiple sclerosis kind used knock almost every days potential benefits seeking first attack years risky treatment reverse longterm effects old knocked cold couldnt move multiple sclerosis far outweighed daily challenges hands legs overwhelmed fatigue disease went china cure surprised fit sportsman visited multiple sclerosis relieve symptoms countless doctors egypt directed seek treatment us diagnosed also highlighted real need safe multiple sclerosis reputed hospital started effective treatment happy treatment taking five shots cortisone roche medicine approved attack longterm benefit dozens use us parts world attacks later left continuous seizures numbness throughout body hopefully come egypt soon nothing treatment looking around therapy involves much research funding pray absence treatment god comes soon multiple sclerosis option decided look around world patients truly suffer lotscience innovation roche sc ie nce innovation translating brilliant idea medicine constitutes complex value chain diverse activities chapter looks steps journey material topics covered chapter product portfolio strategy rd pipeline strategy personalised healthcare contribution un sdgs deep understanding biology disease first step long road towards creating safe effective medicine translating molecule medicine really following pages take look matters patients calls combined creativity examples six major phases steps rd unrelenting perseverance thousands people value chain specialised knowledge broad range areas early discovery latestage development identifying medical need initiating appropriate manufacturing regulatory distribution sales action drug research development rd must tackle understanding underlying biology triggering multitude variables optimised disease tandem experts across roche group shy away creating lead compound right qualities complexity task search cultivating smart partnerships across academia medicine truly makes difference patients lives physicians patients industry innovating accelerating clinical trials beyond countless challenges need mastered developing diagnostic tests health apps scientists labs translating molecule provide deeper insights patients condition medicine demands high degree crossfunctional doctors make best decisions patients teamwork within company often external partners well blazing new trails medical sciences means pushing boundaries knowledge navigating unfamiliar terrain standard textbooks exist provide guidance identifying medical need setbacks failures part process discovery antibiotics starting penicillin learnings derived disappointments rightly considered one greatest medical ultimately propel science ahead resulting achievements th century yet breakthrough medicines miraculous qualities medicines increasingly losing lustre rapidly mutating pathogens roche investigates diseases diverse areas acquiring resistance widely used antibiotics oncology neurodevelopmental neurodegenerative challenge multidrugresistant superbug conditions ophthalmology immunology inflammation addressed conjured regular infectious diseases intervals public debate according estimatesscience innovation roche medical need understanding biology smart partnerships creating lead compound innovating clinical trials diagnostic tests health apps discoverytodelivery value chain deliver value links chain work perfection chapter takes look selection interesting molecules innovative technologies key phases approach major steps million people projected die untreatable starting line commitments bacterial infections weakened hospitalised roche began extensive efforts develop new antibiotics patients suffering underlying diseases often launched several diagnostic tests cobas prone healthcare associated infections hai liat system rapidly identify mrsa hai causing bacteria see spread multidrugresistant strains bacteria methicillinresistant staphylococcus aureus reentering antibiotic space mrsa carbapenemresistant enterobacteriaceae roche significantly stepped efforts hardtoeradicate pneumoniacausing streptococci space last years reviving strong legacy recognised health antibiotic research culminated authorities worldwide crisis public health launches bactrim rocephin emergency demanding combined efforts multiple alliances barda industry declaration players industry hospitals universities amr support internal rd activities governments physicians patients problem tackled successfully addressing unmet need addition several promising preclinical creating new medicines able cure severe compounds roche two antibacterials early multidrugresistant infections would represent clinical development nacubactam severe hardto valuable contribution society treat gramnegative enterobacteriaceae infections antibodyantibiotic conjugate aac unprecedented effort rochealong treatment mrsa aac uses breakthrough companies industry associationssigned technology previously used oncology setting industry declaration antimicrobial resistance antibody tags specific bacterium amr world economic forum davos delivers antibiotic right infected cell followed adoption action compartments becomes activated attack plan number pharmaceutical companies bacteria including roche later year nacubactams dual mechanism action roche also announced entering roche inlicensed nextgeneration betalactamase multiyear strategic alliance barda inhibitor nacubactam meiji seika biomedical advanced research development pharma fedora pharmaceuticals potent authority us department health human inhibitor bacterial betalactamase enzymes services bardas broad spectrum antimicrobials makes ineffective also antibiotic programme aims engage industry partners right inhibiting bacterial cell wall synthesis effort jointly combat rise antibiotic resistance development plan nacubactam foresees development new medicines administering hardtotreat gramnegative diagnostic tests enterobacteriaceae infections recently spread intensive care units across europe us fda given molecule fasttrackscience innovation roche designation endorsing accelerated development plans thus making medicine available physicians patients much earlier summer first patients recruited roches phase study patients complicated urinary tract infections accelerated development plans mean programme move pivotal registration trial directly understanding biology disease human body likened machine mindboggling complexity often currently available antibiotics increasingly losing effect rapidly mutating pathogens works miraculously well things go awry acquiring resistance increasingly bacterial infections become lifethreatening diseases causing disease research scientists called upon understand target repair underlying malfunction error result single missing gene specific cell immune include standard research technologies also system overdrive often could innovative imaging methods sequencing genes combination diverse factors gone amiss well new ways collecting analysing deep data also referred big data suitable target identifying precise biological origin disease therapeutic intervention identified potential diseasemodifying targets hunt design right molecule starts intervention first step modern discovery help automated highthroughput screening medicine roche approach proven stateoftheart computeraided molecular modelling valuable oncology neuroscience ophthalmology thousands chemical molecules created rare diseases albeit quite recent tested short time target identification also consistently used roches immunology research represents start activities development well traditional treatment approaches immune antibodies however different methods mediated diseases focused suppressing whole procedures applied case lead compounds immune system roche contrast aims finding finally chosen undergo iterative molecules finetune system restore multidimensional optimisation achieve best immune balance balance dose exposure side effects efficacy ultimate goal find compound target identification grounded number best possible active structure fits intended different approaches technologies target perfectly well tolerated highly effective wwwunorgpressengadochtm molecule optimisation sma medicine would remain body long enough spinal muscular atrophy sma neuromuscular achieve medical purpose main challenge disease caused missing mutated single gene however human genes alternatively called survival motor neuron smn encodes spliced depend correct splicing smn protein without protein nerve cells specific functions task investigate spinal cord survive resulting muscle potential targets differentiate weakness atrophy sma one frequent spare critical gene results efforts monogenetic rare diseases leading cause published journals science nature infant mortality communications molecule rg received fasttrack designation fda april healthy people smn gene efficient first small molecule rna splicing modifier making sufficient amounts fulllength protein leading tested efficacy phase iii clinical trial normal motor neuron function patients affected sma gene missing critically important smn protein absent well evolution created backup gene rescue gene called smn similar smn gene gene rna splicing creating lead compound right qualities machinery acts differently smn gene new technologies enable scientists better understand translated truncated unstable protein root cause diseases especially cancer increased result amount granular insights vast varied landscape smn protein humans need produced causative disease factors cancer brought creation potentially gamechanging new therapies roche took challenge research project big step closer realisation striking example also advanced one rare diseases novel treatment modality new class personalised portfolio first time ever oral smn splicing cancer vaccines pcv specifically tailored modifier treat sma moving forward tumours individual patients thus taking hopefully help children devastating disease personalised healthcare next level german deep understanding disease biology major biotech company biontech developed novel mrna prerequisite smn alternative splicing programme vaccine approach genentech member roche started back patient organisation group signed strategic collaboration biontech sma foundation initiated discovery programme september codevelop platform company ptc therapeutics november roche gained exclusive worldwide licence attempts developing therapeutic cancer vaccines discovery programme course four years targeting selfantigens tumours notoriously molecule underwent several optimisation steps unsuccessful past cancer cells safety efficacy scientists greatly improved regarded self immune system however molecules ability access difficult areas body scientists identified different type tumour brain also ensured potential antigen called neoantigens encoded byscience innovation roche first time ever oral medicine acquired mutations neoantigens presented immune system seen nonself moving forward hopefully help foreign since tumour neoantigens unique patient molecular fingerprint tumour children sma identified sequencing tumours genome exact fingerprint derived analysis used develop vaccine pcv platform developing biontech designed deliver unrivalled expertise protein engineering mrna code unique neoantigens mabtherarituxan launched using lipoplex formulation allows intravenous genentech time companys first administration injected mrna delivered biotechnologically produced monoclonal antibody immunepresenting cells process present giving true hope people cancer two decades neoantigens immune system cells later roche group portfolio highly recogniseand taught target destroy differentiated biologics recognise tumours express tumourspecific neoantigens one antigen leverage bodys immune system fight disease act transporting proteins emergence personalised vaccines deliver instance toxic payload directly biontech made possible thanks specific target cells combination stateoftheart genomic sequencing modern bioinformatics growing gazyvagazyvaro introduced leverages new understanding cancer biology emergence technology designing controlling type cancer immuno therapy field enthusiasm sugar molecules specific region antibody neoantigenbased vaccines also spurred affinity antibody immune effector cells observations patients higher neoantigen increased triggering death cancerous cells burden respond better checkpoint inhibitors effectively tecentriq thus personalised neoantigen vaccines biontechs potential broadly scientists across roche group continued combined across roches cancer immunotherapy efforts broaden toolbox physicians portfolio research programmes could patients fight cancer developing new classes considered next wave immunotherapy anticancer medicines cancer immunotherapy example new antibodies created july journal nature published results engage immune cells kill tumour cells eliminate biontech study mrnabased vaccine cells suppress immune response generate tested carefully selected melanoma patients immune cells recognise tumour cells one first time eight patients remained promising new cancer immunotherapy platforms tumourfree months late included cell bispecific antibody engineered first patient phase study vaccine target different antigens solid bloodbased rg combined tecentriq solid tumours haematological tumours naryshkin n et al science sivaramakrishnan et al nature communications sahin u et al nature antibody formats also hold promise specific cancer settings terms combination trials approved cancer immuno therapies tecentriq smart partnerships across academia industry researchers facing huge complexity medical sciences today impossible master challenges alone example term lung cancer segmented least different molecular subtypes driven distinct set genomic drivers requires distinct set new bloodbased assay development ultimately help tailor treatment options tailored treatment approaches add abundance specific immune biology individuals tumour targeted investigational compounds available setting confronted almost limitless choices view naturally limited resources one single company collaborations diverse diversity approaches bispecific antibodies partners therefore essential currently developing two cell bispecific antibodies target cd protein expressed seeking securing new firstinclass bestin surface b cells type white blood cell class opportunities address unmet medical need phase clinical development remit partnering units roche pharmaceuticals diagnostics divisions cd cell bispecific tcb based complement strengthen respective internal structural format engineered two rd organisations search transformative antibody fragment fab regions bind cd technologies therapies one fab region binds cd protein plays role cell activation contrast roche pharmaceuticals engaged cd celldependent bispecific tdb structure partnerships worldwide every year several one fab region targeting cd another new collaborations sealed significant proportion fab region targeting cd antibodies divisions sales pipeline result potential longterm differentiator partnered projects goal collaborations haematology could provide level clinical successfully leverage combined strengths benefit patients b cell malignancies beyond internal external stakeholders ensuring mutually current anticdtargeting antibodies new beneficial partnerships ultimately help patientsscience innovation roche advancing personalisation oncology one example collaboration agreement signed roche gns healthcare innovating accelerating clinical trials june roche use gns technology refs emergence entirely new classes drugs reverse engineering forward simulation opening hitherto closed doors highly targeted analyse massive volumes proprietary data treatment options staggered combination regimens electronic medical records nextgeneration development also calling unconventional sequencing data using realworld data approaches clinical trials spacefrom collaboration aims generate unique insights recruitment selection trial participants unravel hidden drivers drug response cancer identification validation novel endpoints progression still many challenging cancers neurosciences central nervous system disorders cdpositive diffuse large b cell lymphoma roche developed strong position hope find new personalised nextgeneration rd last years several factors cancer treatments address challenges complicate exact diagnosis disease setup meaningful trial protocols established strategic alliance foundation medicine fmi roche announced first positive results cancer tissue biopsy taken new assay jointly developed two often reveals molecular underpinnings companies september aim advance example specific genetic mutation contrast personalisation cancer immuno therapy capturing neurodegenerative diseases alzheimers subsequently leveraging progress biomarker disease neurodevelopmental diseases science ultimately helping tailor treatment options autism spectrum disorder affecting brain specific immune biology individuals evident biopsies taken directly tumour facilitated novel assay btmb fortunately alternative methods different bloodbased tumour mutational burden quantitative imaging technologies allow revealing glances clinical marker measures number mutations brain becoming effective within tumour genome oncology clinical trials certain objective btmb biomarker study conducted using endpoints whose change time measured plasma samples pivotal phase ii poplar quite well tumour shrinkage overall survival phase iii oak tecentriq studies tmb found correlate indicative collaborations diverse partners likelihood progressionfree survival benefit immuno therapies tecentriq tmb essential master todays complexity could measured using tumour biopsy using testing approach may possible medical science extend tmb testing significantly patients gandara r et al european society medical oncology esmo congress september madrid spain progressionfree survival neuroscience clinically meaningful change autism area however identification validation medicinal chemists roche groundbreaking endpoints much difficult requiring innovative work vasopressinreceptor antagonists starting thinking collaborative approaches back ultimately succeeded creating small molecule rg balovaptan imaging tau pathology alzheimers disease fastforward molecule tau pathology hallmark alzheimers disease investigated latestage pivotal trials treatment ad certain neurodegenerative disorders individuals autism spectrum disorder asd ad postmortem studies suggest amount common neuro developmental condition specific location tau pathology brain characterised difficulties regarding social correlates types cognitive symptoms interaction communication hitherto overall disease severity present life would behavioural cognitive treatments therefore valuable able detect tau pathology available people autism people living ad order assess disease progression support therapeutic clinical trials discovering designing optimal molecule radiochemists roche identified small molecules major achievement one selectively bind tau pathology amenable going clinic assess molecules radioisotope labellingenabling use positron efficacy potentially improving core social emission tomography pet detect tau people communication challenges faced people living ad autism big challenge measure change context demonstrate lead tau pet tracer currently evaluation balovaptan really improving adaptive behaviours phase observational study study patients needed everyday life make sure ad undergo imaging tracer every positive change clinically meaningful enough six months preliminary data suggest patients caregivers authorities technology sensitive disease progression warrants significant investment required novel valuable technology already latestage development incorporated every ad trial portfolio across roche group including trials crenezumab roche scientists investigated vineland adaptive gantenerumab ro antitau behaviour scales robust useful tool quantify social behaviours communication skills well impact daily living collaboration key players field international consortia cns area identification academic institutions major foundations patient advocacy groups roche scientists collected data validation endpoints requires approximately vineland adaptive behaviour scale results applied rigorous statistical innovative thinking approaches methods estimated thresholds numbersscience innovation roche positron emission tomography pet enables scientists detect tau people living ad time points left right month scans patient axial plane indicative minimal changes agreed aggregated alphasynuclein firstinclass molecule meaningful first time behavioural targets underlying pathology pd halting scale place used clinical trials infectionlike spread neuronal death pd short based successful work roche progressive degenerative disorder central nervous recognised top researchers system cns affecting one people age scientific community well patient groups characterised neuronal accumulation setting new standards progressing clinical aggregated alphasynuclein cns results research area asd january balovaptan wide spectrum worsening motor symptoms received fda breakthrough therapy designation resting tremor muscle stiffness walking difficulties balance problems current clinical assessment standard movement disorder societys unified parkinsons developing diagnostic tests health apps disease rating scale mdsupdrs relies june roche announced start phase ii physician testing patients scale also includes study codeveloped prothena using anti asking patient perceived severity however alphasynuclein antibody rg parkinsons details happens clinic visits disease pd area high unmet need lacks largely unknown roche scientists designed app diseasemodifying treatment binding integrated assessment suite remotely pharmaceuticals clinical pipeline phase phase ii phase iii registration oncology inflammation immunology neuroscience infectious diseases ophthalmology others pipeline new molecular entities nmes covers broad range diseases highly innovative technologies applied create produce active molecules measure capture motor symptoms pd patients outstretched hand phones accelerometer via continuous monitoring smartphone records hand movement passive monitoring pipeline clinicians equipped much sensitive registers signals gait activity mobility without rochecompipeline comprehensive outcome data would ever patient interaction using accelerometer gps possible using oneoff testing short visits sensors get picture patients daily activity neurologists clinic ultimate goal capture far walk often sit get vast amounts data fast reliably monitor value extracted massive data individual treatment response subsequently sets applying machine learning namely toolbox allow personalisation treatments algorithms capable providing interpretable results study sensors indeed detect significant applying machine learning large data sets rest tremor patients clinically scored active tests register signals tremor dexterity tremor basis encouraging results balance among others instance check impact targeting alphasynuclein rg level tremor patient holds phone impact disease progression measuredscience innovation roche using nextgeneration parkinsons app plus review information smartwatch evaluated global phase ii diseases manifest patients study started june first results experience daytoday development obtained far highly promising point bring disruptive change research develop great potential digitisation healthcare approve pay medicines connecting past future since fda granted roche historically roche productive breakthrough therapy designations btds bringing important medicines patients fact expedite development review medicines medicines developed roche included early evidence potential clinical benefit model list essential medicines ample serious lifethreatening diseases roche leads proof twentyfive patentfree industry terms number btds bears include lifesaving antibiotics antimalarials witness innovative power roches worldwide cancer medicines rd efforts clearly reflects value products patients society large recent history proves roches continuous massive investment rd totalling roughly year saw strong flow positive news onefifth sales chf billion group roche regulatory approvals important new level largest single rd budget medicines ocrevus hemlibra well life sciences industry one largest across positive data key clinical studies alur industrieshas borne rich fruit last alex impower nonsmall cell lung years roche new molecular entities cancer kidney cancer well pharmaceuticals rd portfolio tested haemophilia among major highlights hundreds early latestage clinical trials year positive developments tempered number medicine launches trials failing meet primary endpoint three times higher previous however many positive results clinical seven years trials approvals new medicines represent strong validation pipeline time continue legacy drawing world major change industry class pharmaceuticals diagnostics capabilities complemented solid expertise areas next generation sequencing actionable realworld clinical data roche uniquely positioned take positive developments reported personalised healthcare next level represent strong validation era digital technology able increasingly tailor medical treatment needs pipeline individuals small subgroups patientsaccess healthcare roche acce healthcare groundbreaking advances medical science meaningful reach people need material topics covered chapter sustainable healthcare pricing disease awareness treatment education growth strategy emerging markets contribution un sdgs w e develop comprehensive access plans adjusted local requirements embed business strategy according million people lack joining forces make difference access basic healthcare multidimensional roche playing leading role initiative challenge one size fits brings together leading solution complex treatments biopharmaceutical companies along cancer often require sophisticated diagnosis world bank union international cancer specialised training hospital infrastructure control uicc access accelerated initiative successful therapy barriers differ launched focuses improving country country roche focuses locally tailored access treatments noncommunicable diseases solutions access intricately linked ncds cancers cardiovascular diseases healthcare systems work address chronic respiratory diseases diabetes multidimensional challenge access takes un sustainable development goal focusing four key areas reduce deaths ncds third awareness key pillar initiative commitment diagnosis individual companies scale efforts healthcare capacity improve access roche launched new programmes funding one pakistan offer sustainable financial solution needing roche oncology order properly address four factors immunology biologic medicines details need deep understanding root causes people might access medicines another programme conducted kenya diagnostics end systematically apply roche working government access planning framework country country increase access treatment herpositive creating comprehensive access plans breast cancer roche supported comprehensive embedded business strategy date plan addresses awareness diagnosis detailed plans countries healthcare capacity well treatmentaccess healthcare roche breast cancer morocco hiv subsaharan africa diabetes africaasia prm europe breast cancer usa testing asia breast cancer saudi arabia differential pricing egypt breast cancer colombia elderly care japan financial support usa awareness disease diagnosis disease healthcare capacity needs funding healthcare symptoms essential complex vital welltrained teams working investment reimbursement screening early detection ensuring right treatment together right medicines tests critical choice equipment provide best protect patients chances patients financial burden increasing awareness help early detection used local governments increase successful treatment begins awareness understanding cancer impact public symptoms disease visit healthcare help improve healthcare funding professional lack awareness keep patients accessing care roche runs awareness campaigns following agreement key partners builds strong partnerships world united arab emirates roche supporting local improve health authorities reducing cancer mortality conducting workshops educational impact awareness programmes activities awareness campaigns train healthcare demonstrated morocco local roche professionals addition roche partnering organisation partners lalla salma foundation stakeholders dubai cancer initiative provide contre le cancer campaign initiated unlimited access screening cancer treatment breast cancer awareness screening programmes four million people live dubai date free screenings provided one million women enabling early breast cancer diagnosis hundreds successful therapy begins awareness meanwhile middle east developing breast cancer policy project collaboration symptoms disease visit international partners better understand attitudes priorities around cancer region healthcare professional use research develop white paper tracking universal health coverage first global monitoring report june latin america teamed economist however many countries early diagnosis rare intelligence unit raise awareness impact number african countries cancer cancer region presentation patients diagnosed latetoend stage war cancer latam conference bogota addition lack general awareness many highlighted deaths cancer region hospitals clinics simply equipped increase better disease instrumentation qualified personnel needed awareness diagnosis healthcare capacity funding provide treatment placements well partnership collaboration needed roches automated ventana benchmark diagnostic equipment tissue diagnosis immunohistochemistry timely diagnosis ensure right treatment choices ihc respective training programmes critical diagnosis critical complex requiring components support access subsaharan specialist laboratory technicians facilities africa ssa date technicians testing may accessible many people trained impact disease areas proper diagnosis way ensure breast cancer total eight cancer centres right treatment choice made across ssa stateoftheart technology early accurate diagnosis significantly increase breast cancer project initiated roche patients chance survival breast cancer turkmenistan enabled significant improvement example patients survive five years early detection differentiated diagnosis diagnosed early compared diagnosed disease one main pillars project disease advanced stage result introduction ihc diagnostics automated modern diagnosis therapy breast cancer death equipment switching manual system rates dropped us automated testing allowed increase biomarker testing women included patients regional hospitals remote areas country another result modern diagnosis pillar widespread disease awareness campaigns regularly conducted roches support since therapy breast cancer death rates dropped capital ashgabat five regions country resulting increase early breast us cancer detection versus access healthcare roche early diagnosis advanced stage breast cancer vast majority patients survive five years diagnosed early one quarter women survive disease caught late stage diagnostic capabilities place another attended workshops meaningful people get clinic tested conducting clinical breast examinations colombia instance breast cancer causes women screened overall highest number deaths women cancer approach might serve template year however many colombian women aware types cancer well risk factors cancer importance early detection diagnosis improving healthcare capacity limited healthcare infrastructuresuch roche working colombias largest lack healthcare facilities trained healthcare healthcare organisations address issue professionalsis often major barrier accessing providing training awareness campaigns modern medicines diagnostics creating consultorios para la mujer womens worlds poorest countries help overcome consulting rooms throughout country barriers roche established number specialised clinics working towards improved programmes aimed making lasting improvements access early diagnosis improved treatment local capabilities range educating objective reduce barriers hurdles training healthcare professionals regulatory patient may encounter way diagnosis personnel helping establish clinics laboratories treatment hopefully recovery possible strengthening local manufacturing capabilities done working health insurance supply chains companies healthcare professionals providers well government far almost focus increasing local capabilities healthcare professionals attended plenary believe provides sustainable way lectures patient journey programmes addressing local health needs helping develop httpseventseconomistcomeventsconferencesamericaswaroncancerlatam national cancer institute seer available httpsseercancergov statfactshtmlbreasthtml desantis c e et al breast cancer statistics cancer journal clinicians doi caac women undergoing rehabilitation activities following breast cancer surgery healthcare systems future one example negates need healthcare professionals blue tree programme india travel major cities attend necessary ongoing presented example best practice side event medical education dilogo roche reached nd united nations general assembly registered physicians seven unga unique cancer patient support countries across latin america initiative tailored address multiple hurdles patients experience course health infrastructures many countries africa treatmentprimarily around diagnosis affordability capacity meet rising need care adherence project supported noncommunicable diseases including cancer patients roche partnered current healthcare workforce subsaharan africa doctors enabled access treatment would need scaled meet across cancer centres india patients existing need help address acute shortage programme shown increase therapy oncology healthcare professionals roche conducted adherence rates training sessions oncology specialists across region latin america online platform dilogo roche established keep healthcare professionals enabling sustainable healthcare funding across region updated information developed number pricing solutions clinical studies scientific advances congresses personalised reimbursement models prmaccess healthcare roche collaborations insurance firms enable pricing according value medicine brings different indications provide millions patients better international differential pricing sets price medicine according countrys economic access cancer medicines situation purchasing power parity adjusted gdp per capita formula one example hurdle overcome roches collaboration private insurance companies countries afford proper cancer care public coverage may adequate southeast asia example patients diagnosed cancer suffer financial catastrophe die within china four cancer medicinesherceptin year meanwhile medical insurance schemes cover mabtherarituxan avastin tarcevawere less population africa included national reimbursement drug list nrdl first time cancer patients innovative funding solutions china access potentially funding barriers exist find practical lifesaving treatments agreement came result ways overcome georgia entered roches systematic approach identifying local agreement city municipality tbilisi access hurdles creating tailored local plan improve funding herpositive early breast cancer patients eligible herceptin uruguay result commercial agreement programme expanded include breast cancer countrys national resources fund patients receiving perjeta herceptin positive breast cancer patients full metastatic setting offering flexible pricing solutions access herceptin perjeta kadcyla women early breast cancer georgia patients expected receive treatment treated herceptin pursuing time period efforts enable treatment advanced breast cancer patients across country order protect patients financial burden funding needed investment healthcare pakistan launched patient support programme reimbursement medicines diagnostic tests collaboration number partners however many countries provide universal enables us provide funding indigent patients healthcare spreads risk catastrophic disease eligible herceptin mabtherarituxan avastin across population done developed perjeta since august patients parts world countries lacking coverage able receive potentially lifesaving often patients turned away go debt medicines otherwise would reachaccess healthcare roche micha nussbaum roche brazil jobs well making contribution community swiss studied medicine university look sustainable solutions identified zurich always interested translating healthcare bottlenecks caused lack training scientific innovation patient benefits roche organised courses doctors nurses eventually led interlude business community workers across brazil consultant pharmaceutical industry discovered many women picking cancer screening results developed interest brazil began exchange system inform messages programme mba studies huge mobile phones fascinating country many different subcultures brought waves immigrants despite current leveraged international connections economic crisis underlying dynamism invited expert canadas oncology healthcare rewards people take initiative persistent policies share best practices congress joined roche paulo together national public policymakers also commissioned functional experts across company focus benchmarking report economist intelligence expanding access therapy cancer patients like unit brazils current oncology healthcare policies many developing countries brazil rising findings presented local congresses incidence breast cervical colorectal cancer highlight successes well areas improvement partnership brazilian healthcare authorities appreciate working public policymakers working alone roche limited impact partners way helping improve access large country collaborating healthcare continue collaboration federal state municipal healthcare authorities roche transitioned pharmaceuticals brazil public access managers making new position diagnostics difference example reached agreements states gois maranho expand people brazil feel roche access patients advanced oncology treatments longterm commitment see us global negotiations proceeding states local company case also personal connection married brazilian together made detailed analysis every step cardiologist raising two children cancer patients journeyfrom prevention convinced jobs well screening diagnosis treatment try making contribution communityour people roche people talented individuals connected inspired purpose basis success people drive healthcare innovations touch lives millions patients material topics covered chapter employee engagement talent retention compensationbenefits leadership commitments organisational effectiveness contribution un sdgs something special working roche starts culture years remain majority core global people practices principles familyowned swiss company committed simplicity flexibility accountability speed innovation focused long term ensure critical component transformation sustainable future generations technology plays key role offering us asked culture roche employees sophisticated yet userfriendly options provide describe deeply engrained values integrity people easy system access place courage passion also highlight collaboration device time embed mindset thrill working cutting edge science required new practices reshaped inspiration outstanding leadership one ways people interact support provides underpinning shared purpose timely meaningful conversations via check patients need next people working ins dialogue employees managers roche know work contributes breakthrough puts conscious focus four essential themes diagnostic solutions innovative medicines connections capabilities contributions career treat cancer multiple sclerosis host simple powerful framework fosters serious diseases relationships based trust shared ownership also ensures conversations focus also continue receive accolades matters top employer creating excellent environment people year year headquarters leveraging diversity enhancing wellbeing switzerland roche affiliates around world importance mutual respect workplace awarded top marks great place work institute reflected commitment diversity inclusion top employers institute respective di one first major corporations countries us genentech roche europe state di goals publicly recognised highly coveted fortunes made substantial progress achieving best companies work list think beyond physical characteristics qualities make person unique order innovating people practices leverage diversity engine innovation strive addition pushing new frontiers science inclusive workplace individual innovation also present focus respected fully contribute skills people companywide project serves transform experiences perspectives complementing theour people roche support leaders global network screenings fitness centres workplace ergonomic di champions lead efforts within sites evaluations counselling services year functional areas grassroots example one also dedicate special week roche sites globally thing diversity initiative employees collectively focus wellbeing heighten overall globally posted pledges videos awareness importance topic employees positively impacting di learn live well offering participate activities organised local teams ranging want top leadership reflect organisation sports relaxation techniques lectures society whole roche also believes health topics nutrition building firsthand knowledge healthcare environment beneficial help expanding finding desired balance many priorities access treatment guide us life challenging varied person right patients supporting people gain roche firmly supports flexible work arrangements experience living working highgrowth parttime work job sharing flexibility also means developing markets well mature established finding new ways working technology markets strengthen capabilities embed alternative work environments people use video critical understanding conferencing telepresence also engaged several online communities best practice sharing established corporate goals several years ago solving problems virtually connecting increase percentage women leaders colleagues across geographies benefits people recently added focus increasing percentage also environment reducing carbon leaders bring experience diverse markets footprint also progressively introduced work percentage women leadership roles roche environments diverse concepts encourage overall risen since terms leaders collaboration enable quiet well private space breadth experience also achieved foster spirit teamwork innovation initial milestones people importance worklife balance flexibility also means finding new healthcare company believe healthy lifestyle major factor overall wellbeing ways working technology employees basis live well roche initiative tailored site best alternative work environments represent needs may include medical checkups learning leadership development adapting everchanging world roche strive help people realise learning development many dimensions full potential contribute high level roche may stretch assignment organisation evolves fastchanging world challenges employee grow professionally learning integral daily work changing perspectives temporary assignment emphasise continuous building capabilities affiliate another continent microsecondment future managers partner volunteer work africa case pharma employees ensure impactful actions technical operations team representing taken support employees learning employees means learning working professional growth range building efficient way lean manufacturing new connections gaining new experiences may reverse mentoring different classroom courses online learning generations people work together learn one leadership commitments firmly believe person take genuine interest people listen carefully tell truth explain roche deserves great leader every empower trust people make decisions discover develop potential people day strive lead example strive excellence extraordinary results set priorities simplify work consistently demonstrating values congratulate people job well done integrity courage passionour people roche people fiveyear goals based figures representation women key leadership roles representation people established developing region experience key leadership roles top quartile ranking overall employee engagement score measured global employee opinion survey goal baseline another find opportunities leverage newest executive leadership development collective strengths offering kinesis aptly named represents everchanging landscape agility needed kinesis njia new kind leadership leadership response changes development emphasis much less traditional instruction believe every employee deserves great much peertopeer learning personal leader touchstone means roche introspection solving realworld problems found leadership commitmentscreated collaborative effort across company experiencebased leadership development also expect leaders bring commitments focus njia kiswahili path midlevel managers life daily behaviour expectations undergo intensive week rural tanzania reinforced range learning experiences work local counterparts resultsoriented leaders leading roche suite programmes projects expanding screening cervical leaders organisation cancer many participants personal professional impact lifechanging see worldclass talent shaping future enhancing digital capabilities key reason many prospective employees cuttingedge science personalised healthcare join roche choose stay us calibre roche sciencedriven company people work awardwinning constantly looking talent drive next wave scientists pioneering inventions top experts healthcare breakthroughs one important trend professionals various fields study attract shaping industry deep data leadership retain worlds talented people position personalised healthcareusing molecular diagnostics targeted medicines customise therapy individualwe unique position translate deep data patient benefits realise new medical paradigm developing applause recognition reflects enhancing digital capabilities people well recruiting software engineers bioinformatics way work specialists realworld data analysts machine learning experts digital professionals connect purpose recognition job well done powerful motivator contributes great deal overall work satisfaction roche umbrella codelife roche launched number awards extraordinary achievements coding game career website engineers addition implemented innovative programme known present coding skills goal game applause encourages peertopeer recognition employees equip laboratory produce medicines patients send colleagues anywhere world customised thank ultimately attract talented digital professionals notes nominate points redeemed roche winners received opportunity visit online catalogue method recognition works especially company see real laboratories meet senior well many project teams collaborate across national executives number teams participated functional boundaries roche employees made use applause game impressive provided excellent times insights future initiativesour people roche talent strategy pursue recruitment excellence attracting best highly skilled motivated people roche offers highly competitive salary students acquire technical scientific skills performancebased rewards wide needed coming years roche established variety generous benefits tailored needs excellent partnerships universities several expectations various locations countries china spain us may include pension plans health insurance child shape curriculum switzerland roche care onsite medical facilities fitness centres apprenticeship programme achieved strong preventive health screenings transportation results local government requested workplace employees given train additional students provide qualified opportunity buy roche stock discounted graduates apprenticeship programme price many countries successful replicated south korea finally invested futurelab south san outreach programmes young people francisco worldclass experio lab another way shaping future ensuring switzerland give back society help prepare qualified candidates future help next generation scientific leadersour people roche ashley magargee roche singapore think impact magnitude unmet need general manager roche affiliate singapore learned step back look immediately accustomed working fastmoving dynamic solutions different kind leadership environment experience tanzania took needed hereone emphasised working whole new level leadership development tanzanian counterparts replaces programme njiakiswahili pathis decisions delegation listening asking keeping focus ambiguous environment empowering one way role modelling njia partnership roche tanzanian demonstrated structure meeting get government notforprofit organisations ideas table ensure clear individual responsibilities remember one team member part third team roche local particular happy gratifying see healthcare leaders came together rural tanzania developed new skills gained confidence apply leadership skills preventing cervical every day return happy showed much cancer day stay part resources passion longer sixmonth programme learned medical need compelling tanzanian women official local healthcare district part times likely die disease women group newfound skills njia developed countries made convincing case superiors acquiring inexpensive cryotherapy equipment locally based bukoba western shore lake available resources treat precancerous cervical victoria groups focus getting treatment lesions group also included healthcare women nearby island tested positive practitioner went island perform precancerous cervical cells previous njia team cryotherapy convinced saved lives developed materials raise awareness diagnosing disease early among women screening treatment since screened women living islands different approach leadership roche used implementing meticulous reflect experience tanzania project plans work tanzania think impact magnitude things always go planned first unmet need gives renewed energy lake crossing example powerful storm rocked mission roche challenges boat knocked electricity island time moreenvironment roche env ironme nt roche protecting environment legal social obligation integral values material topics covered chapter environmental responsibility contribution un sdgs global company committed mitigating impact environment many years proactively seek new sustainable technologies furthermore invest innovative technologies processes achieve environmental goals conduct training programmes roche employees focus efforts activities many environmental total employees participated issues supporting several worlds serious hours dedicated training average environmental challenges example climate change approximately hours per employee water scarcity pharmaceuticals environment committed continuously monitoring key address environmental issues performance indicators ensure compliance environmental risks mitigated via system standards objectives aim achieve least prevention successful environmental management key performance indicator system ems established proactive ems reduce costs increase efficiency enhance roche ecobalance competitiveness measure impact environment using ecobalance metric developed swiss federal effectiveness ems reviewed frequently office environment compliant expert teams roche site identify risks latest guidelines metric provides us develop mitigation plans dedicated team global view impacting earths audit chemical pharmaceutical diagnostic ecosystems manufacturing facilities plant management local officers conduct frequent checks inspections reached ecobalance goal furthermore developed clear defined reduction compared since process create progress target setting aimed reduce ecobalance goal initiating action plans goals set areas year improvements terms decreasing people environment business challenging energy consumption air emissions volume feasible water consumed well reducing weight chemical waste led improvement compared achieved results despite growing production capacities additional buildings across sitesenvironment roche noise pollution emissions water primary energy emissions air roche ecobalance landfilled waste water consumption fiveyear goals natural capital assessment parts world water becoming increasingly scarce quality gradual decline restrictions around use potential costs ecobalance supply may increase believe important million pointsemployee develop strategy committed assessing water management energy consumption site south san francisco us using gj ffeemployee natural capital protocol internationally agreed framework sets businesses measure monetary value environmental general waste impacts dependencies society kgemployee water consumption memployee goal ffe fossil fuel equivalent weighted water stress changes related respectively swiss ecofactors ecological scarcity methods reducing energy water consumption introducing ecoefficient technologies large proportion energy used diagnostics site tucson us example operations currently comes fossil fuel sources established yearterm agreement oil gas long term however local utility provider allow local site goal fully substitute fossil nuclear energies solarpowered using renewable energy energy renewable sources roche utilises utility provider addition provider wide range practices techniques skills keep validate usage solar power allows roche energy consumption minimum total acquire renewable energy certificates showing energy consumption decreased sales reduction emissions versus fossil fuel usage grew included decrease energy used considerable environmental benefits associated buildings stationary equipment gas fuel oil initiative including expected reduction waste electricity district heating co emissions tucson site four year period starting energy consumption terajoules vacaville us another roche site install solar power arrays since solar plant came online total scope may generated approximately mwh scope electrical energy avoiding carbon dioxide energy scope first five months venture saved consumption gj vacaville approximately usd employee anticipated firstyear savings around scope usd business flights share sustainable energy scope energy generated within facilities eg combustion gas scope purchased energy scope business flights data collected group gj gigajoule focus measures reduce energy consumption parallel decrease co emissions goal nonsustainable sustainableenvironment roche reducing water consumption goal reduce water consumption per employee reached year aim continuous improvement long short term approach manage monitor water use locally even though sites use large volumes water located areas water scarcity adopt conservation reduction programmes according local needs water usage discharge water withdrawn million andreas oeri representative founding family member board directors water consumed shows strong interest sustainability joined safety security health environmental million protection audit thirdparty provider india water discharged treatment plant million organic matter first time roche identified discharged waterways global leader actions manage water treatment sustainably cdp notforprofit global heavy metals discharged environmental disclosure platform awarded roche waterways position years water list cdp treatment kg institutional investors assets usd trillion asking companies disclose managing risks posed end roche sites either working worsening water security companies water implementing programmes reduce water usage list receive highest rating accordance increase efficiency water usage cdps water scoring methodology reducing emissions air water phasing greenhouse gases roche want reduce emissions source greenhouse gases phased support sites required develop action majority greenhouse gases ghg emitted plans closely monitored implementation roche group come energy generation effects consist part co less halogenated hydrocarbons refrigeration plans place able maintain cooling plants low level emissions air achieved far make improvements manufacturing emissions air nitrogen oxides sites approach working since sulphur dioxide increased company reduced halogens halogenated particulates volatile organic compounds refrigerants approximately decreased respectively absolute scope scope ghg emissions upgrading technology reduce environmental harm cut reducing carbon footprint purchasing energyefficient equipment including hybrid cars halogens halogenated refrigerants fire increasing sustainable energy supplies well suppressants ghgs remain monitoring employee travel needs work atmosphere long period time processes since total projects therefore committed reduction use completed resulting avoidance tonnes halogens compared co emissions led estimated cost saving chf million per year halogenated hydrocarbons tonnes site oceanside us successfully installed environmentally friendly freezethaw natural inventory refrigerant systems used drug substance consumed released freezing new units use less energy global inventory including chugai genentech ventana previous ones leading estimated annual electrical savings kwh usd utility cost reduction tonnes carbon dioxideenvironment roche production pharmaceuticals diagnostic products site penzberg germany would possible without clean water co equivalent emissions tonnes scope fuel combustion halogenated hydrocarbons scope pre marketbased locationbased total scope marketbased scope business flights energyintensive utilities waste due changes reporting methodology number different reported compressed air liquid nitrogen reducing waste safeguarding ecosystem aim implement following waste management chemical waste incinerated landfilled strategy activities avoid reduce reuse recycle decreased approximately parallel thermally destroy permit landfilling however weight contaminated soil last resort even inert materials remediation activities grenzach germany well slag ashes environmentalrelated activities site south san francisco us increased approximately discharge wastewater pollutants oneoff activities contributed approximately comply fully relevant regulations including tonnes pretreatment requirements elimination rates wastewater treatment plants good ideas go waste already high various innovative activities underway sites help reach goals often ideas using baseline aim reduce general come within organisation one example waste per employee roches packaging plant kaiseraugst switzerland performance indicator increased approximately syringes prefilled medicines among compared reason increase products packed rejected prefilled syringes likely awareness campaigns aimed repacked means medicine improved reporting category must discarded chemical waste landfilled incinerated waste tonnes employees worked manufacturer packaging machine find way reintroduce rejected syringes packaging process general waste result annual saving almost chf million generated significant reduction chemical waste chemical waste generated contaminated soil construction waste prior data collected separatelyenvironment roche first goal safeguard roches genentech site south san francisco collaborated city south san francisco ecosystem protecting business us environmental protection agency epa reassess whether specific streams wastewater longterm risks biotechnology production processes required collection could instead sent citys wastewater treatment plant mexico china iran hosted former based studies performed epa landfill grenzachwyhlen germany showing concluded wastewater streams remediation approach young scientists way adversely affect citys wastewater treatment share best practice ensure implemented operations elsewhere following collaboration south san francisco pharmaceuticals environment site able reduce wastewater volume traces pharmaceutical products enter collected lessening co emissions environment variety ways including via transportation offsite treatment change manufacturing process improper disposal unused reduces disposal cost almost usd medicines natural metabolic processes per year following normal patient use sharing knowledge investing future roche acting concerns impact switzerland forefront efforts pharmaceuticals environment considering environmental protection due long history entire lifecycle products broad experience coping environmental pollution issues mabtherarituxan herceptin avastin perjeta lucentis monoclonal antibodies generated th international conference chf billion sales belong biogeochemistry trace elements icobte held defined class active pharmaceutical ingredients apis zurich partnered eth zurich exempt european medicines evaluation internationally topranking university switzerland agency guideline environmental risk assessment enable ten phd students postdoctoral scientists low excretion rate judged different countries attend also sponsored present significant risk sewage works surface technical excursion conference participants waters therefore termed benign nature learn corporate responsibility innovative constitute environmentally sustainable compounds approach towards remediating former landfill chemical products however subject rigorous environmental risk assessment young scientists countries including india brazil russia chile japan poland pakistanenvironment roche ben fu roche china engagement lead sustainable contribution local community environmental engineer work waterefficient taps showerheads well safety health environmental officer new carefully planned landscaping reduce overall water roche diagnostics manufacturing site suzhou near consumption wastewater production shanghai fully operational plant treated reused purposes produce highquality reagents immunoassays laboratories hospitals doctors surgeries thanks comprehensive approach suzhou contribute improving healthcare patients aim achieve leadership energy china help us supply products environ mental design leed platinum certificate asian countries highest environmental standard us green building councilfor administration building need look production ensure safe environment working site colleagues feel proud energised well neighbourhood general part team building new site construction site engineering teams beneficial impact patients shape put safety first course six million hours environment positive way enhance work serious accident needed reputation china engagement lead recorded due part speakup culture sustainable contribution local community encourages workers point potential safety issues part job take holistic approach safe achieving highest standards sustainability guarding health employees includes outset manufacturing site programme deal air pollution air quality suzhou designed meet highest environmental guidelines accurate information source standards reduce energy consumption employees check air quality via popular installed thicker insulation legally required social app wechat air purifiers installed solarprotective glazing fixed window shadings offices financial support offered employees decentralised air conditioning switches buy home use air filtration masks used efficient led lighting shuts one available charge present photovoltaic panels roofs produce enough electricity sunlight cover dont yet family someday child energy needs administration building enough asks job say look sky power almost private homes entire year used grey father helping keep bluecommunity engagement roche community e ngage nt foster innovative philanthropy makes longterm sustainable difference communities around world material topics covered chapter community engagement contribution un sdgs roche common purpose make difference lives patients families society large global local philanthropic efforts local impact matters whether one common focus strengthening communities support potential individuals organisations make longterm sustainable difference strengthen local communities form strategic innovative interventions partnerships make difference aim build stronger communities strengthening local communities environments partnering local authorities strengthening communities operate nongovernmental organisations ngos whether infrastructure support training respecting local customs needs educationis important part roches responsibility engage employees appropriate global citizen thinking globally acting skillsbased volunteering capacitybuilding locally perspective best exemplified annual projects inspired long deeplyembedded roche childrens walk company sites history philanthropy countries came together donate funds childrens education health initiatives employees approach recognised externally raise money individually company matches achieved maximum score funds raised campaign corporate citizenship philanthropy dow jones sustainability indices gold since first companywide walk standard measure corporate sustainability roche employees participated raised compares industry average chf million total proud additionally philanthropic activities support global childrens projects nine un sustainable development goals directly supported initiativecommunity engagement roche annual roche childrens walk biggest employee fundraising project money raised doubled company used childrens programmes supporting education health social development around world picture shows roche ambassadors visiting project malawi one example local project benefitted meals centre provides psychological support funds raised walk roche counselling basic skills training family members childrens centre mumbai india roche pharma children place children india partnered notforprofit organisation recover cancer place everyone st jude india childcare centres facilitate learn new way life hold good social initiative providing holistic care children stead future cancer important effort children living cancer india strengthening communities receive proper treatment operate important part centre offers families remote areas india free place stay child receives treatment roches responsibility global citizen addition helping accommodation transport students countries worked theme fostering next entrepreneur hosted international swiss talent forum event provides platform students exchange views learn supporting potential founding sponsor organisations signature also believe supporting potential think tank programme international swiss talent individuals initiatives right time forum brings together motivated young tremendous longterm impact roche encourages people around world address current future leaders innovators reach potential global issues forum hosted students supporting scholarship programmes empowering nations focused theme fostering organisations employee volunteer programmes next entrepreneur science engagement initiatives contribute good partnership roche provides example one roches longer partnerships schweizer jugend forscht support practical area collaboration schweizer matters one employees completed skills jugend forscht swiss youth science yearold based volunteering assignment foundation foundation focuses identifying potential providing pro bono consulting advice business young scientists inspiring innovation roche marketing process improvementscommunity engagement roche partnering make difference developing countries volunteering programmes making sustainable difference entails partnering combine capabilities skills roche communities ngos local authorities initiatives employees ngos build capacity address local needs capacitybuilding deliver sustainable outputs escalate impact roche offers short longterm volunteering programmes longterm supporter international shortterm microsecondment programme committee red cross icrc founding ngo partners request temporary skillspecific member corporate support group roche consultative support health educationrelated contributed water habitat activities several assignments countries including pakistan ethiopia liberia uganda burundi eritrea guinea mali roche collaborated variety organisations activities aim ensure people affected armed pro bono skillssharing assignments including conflict access clean water proper sanitation icrc schweizer jugend forscht b education sustainable living environments partnerships medicines malaria venture mmv roche paired mmv foundation focused roche contributed icrc projects antimalarial drug development one mali aim improve access clean water procurement experts foundation wanted people projects built upgraded expand knowledge capacity area water supply systems violenceaffected communities academicresearch organisation collaborations personal consumption livestock accelerate drug research agricultural use besides roches support global organisations believe supporting potential believe partnerships employees ngos local communities share knowledge individuals initiatives right time individual skills end offer skillsbased volunteering programmes employees work tremendous longterm impact ngos help improve health education incommunity engagement roche belinda holdsworth roche switzerland teach also learned lot always interested engineering led faces students eager learn used study biochemical engineering university interactive handson practical approach graduation started career process engineer classes simulations group activities helped quickly moved commissioning qualification teach fundamental principles supply chain pharmaceutical manufacturing facilities management lean manufacturing teamwork joined roche operational site manager contract manufacturer located france presented case study dabbawallas hold overall responsibility production activities supply hot lunches workers india using lowtech site lead team technical experts incredibly reliable supply chain case study part mba thought knew inside always looking new challenges outside students raised questions offered insights comfort zone end learned skills never considered teach also based secondment programme managed roche learned lot corporate donations philanthropy applied programme offers ngos opportunity brought home importance diverse ways submit request shortterm skillspecific support thinking solve problems diversity another one health educationrelated assignments passions lead eu division pharma technical women professionals grassroots initiative roche selected microsecondment assignment fosters professional development women organised cooperation b educational partnerships almost three weeks visiting looking back think enthusiasm lecturer operations supply chain topics positive feedback students gives namibia university science technology feeling inspired studies windhoek love africathe natural beauty friendly hopefully future careers final day people special energy tourist different teaching students presented gift small going work shortterm assignment chair symbolised place africa wrapped experience beautiful touching way problemsolving many different perspectives since never taught class little would strongly recommend volunteering nervous first day visiting lecturer experience others want share skills feeling quickly disappeared saw friendly see impact one us makeintegrity business roche integ r ity bu sine integrity compass guides us every aspect business behaviour allows us fulfil purpose serving patients material topics covered chapter compliance drug efficacy safety patient organisation support supply chain management occupational accidents contribution un sdgs w hat compliance general sense means adhering rules regulations roche however goes much deeper compliance means internalising letter work grey areas questions first foremost spirit law part regarding conflicts interest improper advantages daily behaviour thereby making impact discrimination harassment first point oriented means moving formal concept contact line manager recently launched ticking boxes way business course compliance officers aim translate integrity matters every level licence formal guidelines business integrated compliance operate society essential efforts creates positive impact business practice delivering innovative products patients objective build common understanding roches comprehensive compliance management putting group code conduct practice system compliance guidelines documented roche group code conduct come roche dedicated regional local compliance life decisions employees make every day officers affiliates around world work chief compliance officer keep integrity top mind poland example local compliance officer translates passion job helping colleagues understand topic essential compliance roche selection external distributors instance based ethical sustainability criteria integrated business decisions poland total employees used roche group speakup line available languages countries chief transparency visvis healthcare stakeholders compliance officer received reports relating alleged roche strives mutually beneficial partnerships violations code conduct via business ethics incident diverse groups interact patients advance reporting system incidents unfounded access improve quality care patient group still investigation substantiated result council ensures patient voice integrated employment contracts agreements business partners across entire lifecycle medicines patients terminated grounds unethical behaviour help us understand personal experiences andintegrity business roche challenges posed disease provides us invaluable insights help us improve product development clinical trial programmes dialogue physicians essential increase knowledge effectiveness safety current therapies diagnostics also prioritise discovery efforts accordance industry guidelines make details interactions patient organisations public strengthened internal control verification processes interactions healthcare professionals organisations addition also developed guidance affiliates communicate impact healthcare contributions transparent way contributions healthcare stakeholders maintain high marketing standards engaging healthcare professionals published online see link rules around ethical business practices become complex difficult employees reported promptly appropriate regulatory keep overview compliance officer roche authorities roche employees required belgium tackled challenge creating document report drug safety quality issue immediately using simple icons common topics complete annual awareness training adverse educational grants promotional events meetings event reporting healthcare practitioners employees click icon connected internal repository embedding human rights business see key compliance criteria approval roche fully committed supporting respecting workflow required forms condensed version human rights within sphere influence also created specifically use sales includes labour rights freedom association representatives established methodology strengthen human rights risk assessment relevant healthcare roches safety risk management department suppliers service providers way contributions systematically monitors roche medicines increase transparency along supply chain based rochecom worldwide patients suffer side effects impact assessments operations integrate performance adverse events captured global database findings internal business functions htmtabidtab ensuring business continuity improving operational resilience data show roche continues solid employee health safety track record key health safety performance indicators also help employees stay safe private lives campaigns increasing night visibility preparing home emergencies addition established threat assessment team process roche basel employees security concerns workplace home site security officers western european sites discussed measures protect logistics network intellectual property accident rate number workrelated accidents well training adequate security measures working days lost per year due accidents sales marketing organisations ensuring quality manufacturing mental wellbeing workplace pharmaceuticals diagnostics among employees engaged able cope highly regulated industries addition regulations challenges work perform better fda ema countries happier overall reason roche began requirements staying aligned ever implement mandatory workplace mental health risk changing regulations requires precise communication assessments affiliates emphasis planning execution global scale well preventing burnout depression mental issues training highly qualified technicians prepare early identification problem sites medicines sterile rooms need special certification screen employees questionnaires others hold like aeroplane pilots technicians must work discussions small groups someone risk certain number hours per year take tests identified indepth discussions managers ensure maintain high standard external experts sites also offer hour helpline employees call anonymously pharma technical operations alone people audits mental health protection began roche work quality compliance sites around sites around world resulting best practices world includes internal auditors regularly shared among affiliates inspect manufacturing sites ensure adherenceintegrity business roche roche quality standards often tougher personal data refers personal data required law launched potential roche stakeholders including employees project collaboration fda ensure patients ensure adhere stricter inspection readiness workstreams production regulations embedding data privacy governance system facilities equipment quality laboratory business develop training modules system materials management ongoing employees developing medicines efforts include speeding corrective preventive tap huge amounts patient data genomic actions issues identified information get access valuable information long continue uphold roche different manufacturing sources trust placed us always protecting respecting supply products event natural disasters individuals privacy process use unforeseeable events use personal data manufacturing sites appropriate capacity level contract manufacturing sites cover emergencies sudden increases demand also maintain safety stockpiles products raw general managers lead compliance materials backup equipment set helps need deliver lifesaving medicine crucial diagnostic test emergency roches decentralised structure general managers gm safeguarding data personalised healthcare affiliates play important role ultimately data privacy fundamental human right responsible compliance brazil example gm works protection responsible use personal data local compliance officer ensure every employee anchored roche group code conduct adequately trained feels comfortable asking questions reflected daily operations response gm regularly reviews compliance cases management meetings european unions new comprehensive general data asking direct reports would leads protection regulation comes effect may example showing roche interested unethical roche embarked companywide project business deals zero tolerance employees cross meet detailed requirements including line noncompliant behaviour clear message documentation assessment processing everyone compliance good business developing lasting partnerships fostering engagement roche depends network business see suppliers service providers critical suppliers service providers addition partners go beyond standard concept ensuring compliance quality standards audits conducting supplier sustainability assurance also expect adhere high principles visits assurance visits aim build trust add ethics labour environment health safety valuein contrast conventional audits often management systems well mitigate risk seen policing acts made visits ensure business continuity principles least one every second working day around world covered detail roche supplier code conduct suppliers service providers constructive engagement governments required adhere roche wants make voice heard inform public discussion healthcare aim help advance regulatory framework healthcare ensure sustainable development industry actively engage public discussions memberships engaging political institutions trade industry associations efpia medtech europe bio government affairs teams us eu advocates policies roche remains independent political affiliation ensure patients access medicines support associations political institutions transparent diagnostic tools need goal inform dealings switzerland spent chf million lawmakers policymakers advocacy organisations includes payments industry associations various potential impact policies biomedical chambers commerce financial assistance trade unions innovation patients serve roche donations political parties cantonal federal level employees involved lobbying efforts must comply donations political parties low doubledigit applicable laws regulations eu thousand range swiss francs together accounted amount funding policyrelated activities approximately total contributions donations documented eu transparency register see link us lobbying expenditure federal initiatives approximately usd millionintegrity business roche addition genentechs political action committee roches good government committee allow recognition business ethics employees voice encouraging election legislators funded solely voluntary mexico employee contributions governed independent board contributed approximately usd federal political candidates confederation industrial chambers united mexican bipartisan manner states awarded roche mexico ethics values award purpose award highlight best practices accelerating access treatment ethical business companies different sectors time government healthcare budgets assessed roche mexico multinational increasingly stretched health technology assessment company pharmaceutical industry receive recognition hta important tool policymakers weighing evidence clinical effectiveness safety costeffectiveness therapies approved regulatory agencies eunethta established create network hta across europe including homogenous approach relative effectiveness assessment currently hta national acted trusted partner example regional bodies europeeach using different fda participating industry representative criteriawhich potentially slows access drafting newest iteration newly approved medicines prescription drug user fee actthe key source funding medicine review process addition roche collaborating eunethta roche working fda foster greater focus pilot one hta body authorised developing therapies children cancer relative effectiveness assessment shares report hta bodiesavoiding duplication europe direct interactions ema take effort pilot study focus lung cancer place example scientific advice medicine alecensa pilot help roche learn eus priority medicines prime scheme local regional needs hta supports accelerated regulatory approvals eu transparency process achieve greater harmonisation roche actively fosters publicprivate exchanges register mitigate redundancies speed access information innovative medicines eceuropaeu initiative imi efpia member transparencyregister collaborating regulatory agencies drug information association cochair publicconsultation members development regulatory teams meeting basel focusing collaboration displaylobbyist work closely agencies around world roche regulators hta bodies payers doidintegrity business roche funke abimbola roche uk compare role compliance orchestra conductor british citizen nigerian descent come listen occasional notes key family parents three siblings make individuals aware take corrective well several uncles cousins physicians action needed decided career law lot convincing age determined compliance crucial protecting reputation become lawyer opportunities patients need know products meet standards offered achieving social justice profess physicians need convinced rely us patients life stake regulatory support family attended top uk reimbursement authorities need assurance university graduating honours law degree transparent act good faith rude awakening couldnt find conduct business upholding high levels job discrimination due race managed integrity make sustained contribution society find position within respected inhouse legal measured sales figures team another shock returned maternity leave london firm worked outside work spend great deal time speaking still expected long hours impossible young people across britain difficulties working mother left london work regional career overcome barriers also firm regular working hours share story senior leadersfrom members parliament chief executivesand suggest ways embedding compliance daily work get involved levelling playing field joined roche us compliance means advancing equality proud son respecting spirit well letter laws recognised school leadership governing industry different implications supporting others championing equality people diverse jobs research clinical development sales proactive communication stunned humbled news making right decisions relevant compliance awarded queens honour situations important appointed member excellent order british empire mbe equality work often compare role compliance helping young people reach potential orchestra conductor time people opened new doors positively impact many sync playing harmoniously job peoplecorporate governance roche cor porate gove r nance principles roches corporate governance principles put focus corporate governance requirements particular business activities sustainable value creation applicable laws swiss stock exchange innovation prescribe management culture six swiss exchange directives swiss code conforming recognised standards good corporate best practice corporate governance promulgated governance policy transparent communication swiss business federation economiesuisse principles build basis successful companys internal governance framework particularly implementation roches commitment serving articles incorporation bylaws embodies stakeholders principles needed ensure companys businesses managed supervised manner strong board directors represents consistent good corporate governance including interests shareholders stakeholders necessary checks balances highly skilled managers act integrity extremely important printed annual report contains selected links roche website wwwrochecom readers th consecutive year roche thus provided snapshot recognised dow jones sustainability indices company reporting date also directed group leader sustainability within sources consult time pharmaceuticals biotechnology life sciences uptodate information corporate governance industry sustainability core business roche whereas annual report covers single practices award reflects commitment financial year ending december website running business way ethical responsible contains information permanent nature creates longterm value stakeholders well latest roche news companys articles incorporation bylaws curricula vitae corporate governance report sets members board directors corporate structures processes rules roche takes executive committee published website basis wellfunctioning corporate governance roche complies relevant details please refer following report annual general meeting annual general meeting board directors board directors board committees presidium nomination committee board committees remuneration committee audit committee corporate governance sustainability committee corporate executive corporate executive committee ceo ceo ceo general committee cfo hr roche group pharmaceuticals diagnostics counsel enlarged corporate executive committee enlarged corporate gred pred partnering communications executive committee chugai rochecomgovernancecorporate governance roche board directors th annual general meeting agm march forthcoming agm roche holding ltd march shareholders board directors nominates chairman reelected dr christoph franz chairman remaining members board directors board directors reelection furthermore agm reelected andr hoffmann moreover board directors nominates prof sir john bell julie brown paul bulcke prof dr dr christoph franz andr hoffmann richard p lifton dr andreas oeri bernard poussot prof dr richard p lifton bernard poussot dr severin schwan dr claudia suessmuth dyckerhoff peter r voser reelection members peter r voser elected anita hauser new remuneration committee agm member board directors term one year provided articles incorporation previous year board directors prof dr pius baschera stand reelection nominates bdo ag independent proxy period conclusion addition agm elected dr christoph franz ordinary annual general meeting shareholders andr hoffmann prof dr richard p lifton bernard election agm poussot peter r voser members remuneration committee organising meeting immediately following agm board directors determined structure composition remaining committees shown see also pages board directors corporate executive committee composition name year birth first elected board directors dr christoph franz c e chairman andr hoffmann representative c e vicechairman shareholder group pooled voting rights dr andreas oeri representative e shareholder group pooled voting rights prof sir john bell b e julie brown b e paul bulcke b e anita hauser e prof dr richard p lifton c e bernard poussot c e dr severin schwan f dr claudia suessmuth dyckerhoff b e peter r voser c e secretary dr gottlieb keller board directors honorary chairman dr fritz gerber board directors corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson corporate executive committee memberships corporate executive committee remained unchanged information member corporate executive committee enlarged corporate executive committee listed see also pages board directors corporate executive committee composition name year birth position since corporate executive dr severin schwan ceo roche group committee daniel oday ceo roche pharmaceuticals roland diggelmann ceo roche diagnostics dr alan hippe chief financial officer cristina wilbur head group human resources dr gottlieb keller general counsel enlarged corporate osamu nagayama chairman ceo chugai executive committee dr michael varney head genentech research early development gred prof dr john c reed head roche pharma research early development pred dr stephan feldhaus head group communications dr sophie kornowskibonnet head roche partnering secretary corporate perolof attinger executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge john morris ian starkey since mark baillache business year chief compliance officer dr urs jaisli corporate executive corporate executive committee ceo ceo ceo general committee cfo hr roche group pharmaceuticals diagnostics counsel enlarged corporate executive committee enlarged corporate gred pred partnering communications executive committee chugaicorporate governance roche group structure shareholders roches operating businesses organised shareholders related parties pages two divisions pharmaceuticals diagnostics note financial statements roche pharmaceuticals division comprises two business holding ltd significant shareholders six exchange segments roche pharmaceuticals chugai whereas addition significant shareholders published regulation genentech former third segment relevant webpage disclosure office sixexchange integrated roche pharmaceuticals diagnostics six exchange regulation regulationcom division consists following four business areas significant centralised point care solutions formerly andr hoffmann vicechairman board shareholders named professional diagnostics molecular directors chairman remuneration diagnostics tissue diagnostics diabetes care committee dr andreas oeri member board directors chairman boards business activities carried group corporate governance sustainability committee subsidiaries associated companies detailed serve respective capacities board information roche holding ltd significant committees representatives shareholder subsidiaries associated companies including group pooled voting rights receive company name listing information domicile share remuneration set forth remuneration report capital equity interest listed finance finance report note report note roche group consolidated roche group consolidated financial statements financial statements list subsidiaries related parties exception associates dr jrg duschmal works postdoc roche relationships exist shareholders major shareholders listed finance report pooled voting rights notes roche group consolidated financial statements equity attributable roche crossshareholdings roche pharmaceuticals incl genentech pharmaceuticals chugai centralised point care solutions molecular diagnostics diagnostics tissue diagnostics diabetes care composition capital structure information roches capital structure provided nes holders described articles finance report notes financial statements incorporation roche holding ltd roche holding ltd additional details contained articles incorporation roche information debt instruments holding ltd issued outstanding bonds provided finance report note roche group movement recognised amounts last consolidated financial statements debt three financial years detailed finance report notes financial statements roche information employee stock options provided holding ltd finance report note roche group consolidated financial statements equity company share capital chf compensation plans including detailed divided fully paid bearer shares information stocksettled stock appreciation nominal value chf restrictions rights ssars plan roche restricted stock unit exercise voting rights shares upon rsu plan roche performance share psp plan deposit shares voted without restrictions roche connect roche option plan authorised conditional capital roche issued options apart employee stock options described finance report addition nonvoting equity securities note roche group consolidated financial nes issued bearer form statements equity compensation plans form part share capital confer voting options issued connection debt instruments rights nes confers rights one share participate available earnings neither options awarded employees liquidation proceeds following repayment share debt instruments issued capital roches nes rights pertaining thereto effect roches share capital including provisions protecting interests rochecomarticleofincorporation rochecomboardofdirectors rochecomexecutivecommittee rochecomarticleofincorporation rochecomannualgeneralmeetings rochecomarticleofincorporation rochecomcommittees rochecomarticleofincorporationcorporate governance roche board directors corporate executive committee information member board directors years preceeding current reporting period member corporate executive lack existing business connections committee listed pages members group subsidiary independent roches board directors age limit restriction board directors independence definition based term office curricula vitae current definition swiss code best practice former members last five years corporate governance economiesuisse bodies information including information complemented specific preceding criteria years first election board members see rochecomboardofdirectors additional positions memberships activities available continuously updated internet principles governance principles delegation competence reservation powers management rules pursuant article para point vegv group companies executive bodies number permitted activities board company include economic environmental directors corporate executive committee social topics principles together internal members outlined articles organisation board directors division incorporation roche holding ltd authority responsibilities board management remits board committees since annual general meeting elected information control mechanisms available members board directors chairman board dealings corporate management board directors members governed bylaws remuneration committee annual basis elections nominee voted separately board directors roche holding ltd see articles incorporation roche organised ensure group conducts holding ltd minutes th annual businesses responsibly focus longterm general meeting roche holding ltd held value creation end roche board march delegated certain responsibilities several committees composition chairpersons december exception dr severin schwan none described committees members board directors office authorities responsibilities defined detail end member roches corporate bylaws board directors executive committee served executive capacity group subsidiary five financial committees chaired independent directors board directors board directors board committees presidium nomination committee board committees remuneration committee audit committee corporate governance sustainability committee corporate executive corporate executive committee committee according bylaws board directors auditors findings presented audit board meeting may convened without chairman committee full board details risk present request members roche management including risk factors risk board meets year assess chairmans management policy see risk management performance meeting attended website financial risk management specifically chairman chaired vicechairman described finance report system internal controls financial reporting part management information system mis see pages finance report board directors regularly informed internal audit important issues sales performance etc group audit reports general counsel board access electronic information platform direct access gives regular briefings audit provides timely information board committee corporate governance directors boards committees sustainability committee ongoing activities system controls set forth audit reports chief audit risk advisory executive attends audit committee partly board directors established system corporate governance sustainability controls continuously monitored committee meetings external auditors audit committee corporate governance group audit independent appraisal function sustainability committee board evaluates reviews groups activities directors consists following elements service management annual audit plan report operating financial risks risk yearly defined focus areas eg market access third management system party management validated senior management roche group established risk management presented audit committee roche process covering entire company system group committed maintaining high standard place identify manage type risks internal control throughout worldwide potentially affecting business including economic operations management responsible assessing environmental social impacts risks business risks aspects operation opportunities containing stakeholder input implementing effective efficient processes board directors highest governance controls whilst ensuring compliance internal body involved roches risk management policy sets external rules regulations approach accompanying responsibilities conducting operational audits group audit pharmaceuticals diagnostics divisions determines managements response risks global functions conduct formal risk assessment surrounding business processes systems process least year must develop risk evaluates appropriateness completeness plans material risks efficiency processes controls action plans monitored deviations reviewed regular implement necessary changes enhancements performance dialogues consolidated group risk developed together businessauditee report including target risk profile discussed tracked completion corporate executive committee approved statutory auditors see together group business plan material chief compliance officer compliance officers risks reviewed board yearly basis subsidiaries see effectiveness risk management process safety health environmental protection monitored group risk advisory team department overall process regularly reviewed external corporate sustainability committee rochecomriskmanagement additional information provided finance report note roche group consolidated financial statements risk management rochecomenvironment rochecomsustainabilitycorporate governance roche science ethics advisory group seag board directors met meetings issues relating genetics genetic engineering generally hours length including fullday meeting addition day visit members corporate executive committee major subsidiary invited attend meetings board board committees met follows directors report person agenda presidium board directorsnomination items concerning situation warrants committee meetings approx hours members enlarged corporate executive remuneration committee meetings approx committee may also invited attend board hours committees invite chairman board audit committee meetings approx hours corporate executive committee members deliver reports committee meetings may elect corporate governance sustainability commission independent expert reports call committee meetings approx hours services consultants board directors regularly conducts year several blackout periods imposed assessment selfassessmentassessment third parties senior employees prohibited via electronical survey personal interviews trading company stock following blackout performance selfassessment board periods effect directors addition selfassessment december february audit committee conducted april april june july members corporate executive committee october october maximum ordinary notice period twelve months blackout periods changed chairman changeofcontrol clauses board directors circumstances warrant employment contracts management contracts fall within scope subsection annex six directive information relating corporate governance rochecomethicalconflicts remuneration committee members recuse deliberations decisions matters affect interests figures indicate actual length meetings include directors extensive premeeting preparations postmeeting followup activities dr andreas oeri chairman corporate governance sustainability committee sheaudit india photo gak board board committees attendance corporate presidium governance nomination remuneration audit sustainability board committee committee committee committee number meetings ch franz hoffmann j bell j brown p bulcke hauser since march rp lifton b poussot schwan oeri c suessmuth dyckerhoff p r voser retired board members retired march p baschera member committee invited guest board committee meetingscorporate governance roche remuneration shareholdings loans rules aol details regarding remuneration shareholdings loans content method determining content board cec compensation shareholding programmes rules principles basic principles elements compensation applicable performance shareholding programmes serving former related pay members board directors corporate rules principles executive committee together description allocation equity securities authorities procedure determining convertible rights options set forth separate remuneration report additional amount payments pages finance report notes members executive roche group consolidated financial committee appointed statements equity attributable roche shareholders vote pay general related parties pages listed meeting shareholders note financial statements roche holding rules loans credit facilities ltd board executive shareholdings postemployment benefits rules vote pay following rules remuneration shareholdings agm loans board directors board corporate executive committee cec set forth articles incorporation aoi participatory rights shareholders participatory rights shareholders defined articles incorporation roches articles incorporation roche shareholders representing shares nominal value shares issued bearer restrictions least chf million request placement admission annual general meetings items agenda annual general meeting exception shares must deposited within must done later days specified period date meeting date meeting admittance card must issued shareholders name provided articles rules issue instructions incorporation shareholder elect independent proxy rules electronic represented third party annual general participation agm laid meeting corresponding invitation agm regulated articles incorporation articles incorporation contain restrictions exercise voting rights quorum requirements stipulated conformity swiss code obligations rochecomarticleofincorporation change control defensive measures articles incorporation contain provisions would terminated event acquisition mandatory bid rule swiss law applies vesting period restrictions preexisting awards would removed options could changeofcontrol clauses exercised immediately components remuneration based roche nes relationship statutory auditors annual general meeting roche holding ltd reports statutory auditor consolidated march shareholders voted appoint financial statements financial statements kpmg ag kpmg statutory auditors based found pages respectively existing legal requirements swiss code years finance report obligations article concerning maximum term office seven years auditor charge kpmg received following remuneration ian starkey auditorincharge since business year services statutory auditors roche holding ltd replaced mark baillache starting auditors roche companies business year information long including chugai auditors auditorincharge serving capacities provided statutory auditors participate audit committee meetings millions chf prepare written oral reports results auditing services audits audit committee oversees auditrelated services assesses auditors makes recommendations assurance board information authorities non statutory audits responsibilities audit committee see article tax services bylaws statutory auditors participated services meetings audit committee total rochecomarticleofincorporationcorporate governance roche statutory auditors elected year services include advice relating process annual general meeting improvements regulations trainings auditing services provided legally required company formal policy governing engagement statutory auditor nonaudit auditrelated services include assurance accounting services policy prohibits certain services services provided auditors provided permits certain services necessarily provided statutory auditor limits agreed audit committee services go beyond legal requirements could potential nonaudit service engagement reviewed include attestation services comfort letters policy authority proceed consents consultations given tax services include services respect compliance tax returns tax advice except services related audit tax relationship independent proxy recent years bdo ag served independent rules issue instructions proxy annual general meeting independent proxy rules electronic march shareholders elected bdo ag participation agm laid independent proxy period corresponding invitation agm conclusion ordinary annual general regulated articles incorporation meeting shareholders bdo ag paid services annual general meeting according expenditure totalling chf chf information policy provided articles incorporation relevant information documents including corporate notices published swiss official media releases investor updates presentations gazette commerce daily newspapers analyst investor conferences available designated board directors basler zeitung internet publications available finanz und wirtschaft lagefi le temps neue rochecompublications ordered zrcher zeitung email fax baselwarehouseservicesrochecom fax roche reports halfyear fullyear results business reports published print andor online contact address investor relations formats media events addition detailed f hoffmannla roche ltd investor relations firstquarter nine months sales figures group finance basel switzerland published year april october tel current list publication dates available fax english german internet additional information including details specific contact persons available internet rochecomarticleofincorporation rochecommedia rochecominvestors rochecominvestorscontactscorporate governance roche chief compliance officer compliance officers network chief compliance officer compliance addition roche established business ethics officers network committed ensuring incident reporting beir system enables roche group code conduct consistently chief compliance officer capture track complied throughout roche group also monitor alleged violations initial reports serves contact person shareholders employees local compliance officers resolution customers suppliers general public issues relating implementation compliance business ethics incidents recorded system code employees parties become group internal investigation department aware violations roche group code conduct regionallocal management receives specific bring attention managers concrete information alleged violation supervisors local compliance officer report roche group code conduct one certain pre chief compliance officer dr urs jaisli defined categories corporate governance direct phone number email sustainability committee audit committee ursjaislirochecom disclosures treated board directors informed substantial confidentially addition end violations managements corrective actions made employees may anonymously report irregularities complaints mother tongue via speakup chief compliance officer reports general line starting december new compliance counsel also submits regular reports tool group level socalled roche group code corporate governance sustainability committee conduct help advice line introduced needed audit committee board strives provide guidance case questions directors uncertainties interpretation roche group code conduct reference documents furthermore serve platform ideas suggestions concerning documents nonapplicabilitynegative disclosure expressly noted information contained provided six swiss exchange corporate mentioned herein either nonapplicable governance directive commentary thereto omission construed negative declaration rochecomcodeofconduct rochecomriskmanagementremuneration report roche mune ration por material topics covered chapter executive remuneration principles roches success depends substantially global company like roche marketcompetitive expertise motivation performance remuneration plays key role along employees conviction forms basis performancebased transparent compensation compensation policy structure ensure compensation packages competitive structure individual roche aims remunerate employees fairly components regularly benchmarked swiss transparently line market conditions european international criteria remuneration enable participate appropriately guidelines underlying principles also companys success pursue goal providing subject regular outside comparisons competitive performancebased resultsoriented compensation however compensation policy one factor safeguarding roches future success another key strive balanced mix fixed variable element corporate culture offers employees compensation components geared employees conditions make best possible position management responsibility contribution shared corporate goal improving healthcare patients includes sound value firstly variable components intended create system based integrity courage passion additional financial incentives achieve corporate time decentralised management goals keep innovation consistently high approach plays major role wide scope compensation level increasing value company individual decisionmaking respectful interactions policy creates stakeholder groups secondly order openness diversity wideranging training rochecomrewards allow employees managers participate development opportunities attractive working companys business success adequate compensation environment unidimensional diminishment sound value system measures key objectives incentivised questions remuneration would fall far short rochecomliving annual bonus payments longterm sharebased ourvalues programmes roche committed fair performancebased resultsoriented compensation policy links employees interests various stakeholder groupsremuneration report roche remuneration decision process approval framework overview terms longterm oriented performance year remuneration committee roches share plan psp awards decided annually board directors decides remuneration board board directors acting upon recommendations members members groups corporate remuneration committee executive committee remuneration decision process approval framework beneficiary remuneration board directors bod corporate executive decision approval components chairman c committee cec incl ceo roche group base payremuneration bonus c remuneration committee stocksettled stock appreciation rights annual general performance share plan board directors upon meeting recommendation remuneration committee decisions pension c remuneration committee remuneration committee tracks market data since total aggregate amounts based salaries leading global pharmaceutical decisions submitted general companies major swiss companies meeting approval implementing ordinance reports findings full board external excessive compensation listed corporations consulting firm pricewaterhousecoopers pwc verordnung gegen bermssige vergtungen bei assists remuneration committee roche brsenkotierten aktiengesellschaften vegv performing market comparisons advising general meeting shall vote annually binding information remuneration committees remit effect approval remuneration powers procedures making remuneration board directors resolved board decisions found bylaws roche directors corporate executive committee board directors articles details see incorporation also outlined sections principles governing specific remuneration components see peer set abbott laboratories abbvie amgen astellas astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer sanofi takeda change composition peer set compared abb credit suisse lafargeholcim nestl sonova straumann swiss ubs zurich insurance rochecomarticleofincorporation rochecomarticleofincorporation andr hoffmann chairman remuneration committee peer set abbott laboratories abbvie abb amgen credit suisse astellas lafargeholcim astrazeneca nestl roche bayer sonova bristolmyers squibb straumann eli lilly swiss glaxosmithkline ubs johnson johnson zurich insurance merck co peer set novartis pfizer sanofi takeda market comparison companies salary assessment pharma peer set major swiss companiesremuneration report roche procedure submitting total board retrospective approval executive remuneration shareholder approval total aggregate bonus amounts corporate annual general meeting executive committee chairman board year annual general meeting agm directors financial year ended shareholders approve total remuneration submitted retrospectively ordinary agm board directors corporate executive separate binding approval committee decided board directors remuneration committee board directors prospective approval respectively board executive aggregate remuneration submitted prospectively agm separate according approval agm roche binding approval period two committed obtaining separate binding ordinary agms shareholder approvals total remuneration paid board directors corporate executive committee follows approval total remuneration annual general financial year financial year meeting retrospective chairman bod c c bonus financial year total amount bonus corporate executive committee cec including ceo roche group cec bonus bonus financial year total amount prospective board directors bod including c bod base payremuneration aggregate total remuneration agm agm base payremuneration corporate executive committee cec including cec ceo roche group base pay aggregate total remuneration agm agm ssars psp base pay indirect benefits stocksettled stock appreciation rights ssars performance share plan psp indirect benefits agm agm agm remuneration components overview remuneration elements lti remuneration components intended remuneration members board sustainably homogenously longterm oriented directors corporate executive committee align managements interest shareholders composed following elements concrete holders nonvoting equity securities give composition see chart composition participating managers additional incentive remuneration board directors achieve value growth form longterm total corporate executive committee shareholder returns fixed base salary complemented annual variable bonus shortterm incentive sti perennial variable remuneration elements ssars psp longterm incentive lti remuneration components linked employees performance companys financial performance commercial success thus align interests roche employees shareholders composition remuneration board directors corporate executive committee annual remuneration elements description c bod ceo roche group cec base pay monthly payment q uarterly remuneration see payments bonus annual payment years years cash see blocked shares blocked shares pensions etc see perennial remuneration elements stocksettled stock see appreciation rights ssars performance share see years plan psp blocked non voting equity securities sharesremuneration report roche variable sti base salary bonus indirect benefits employer contribution lti pensions insurance contributions stocksettled stock roche connect roche appreciation rights tax consulting services performance share plan remuneration expense allowances components others childrens schooling costs foreign tax obligation ahvivalv fixed base pay fixed achievement measurable qualitative base pay cash payment determined individual functional performance objectives position based salary market data leading competitive reasons roche disclose global pharmaceutical companies see footnote individual performance objectives members major swiss companies see footnote corporate executive committee chairman reflects individuals abilities experience performance time pay adjustments likewise december end reporting year linked individual performance take account january following reporting year remuneration prevailing market conditions companys committee decides bonuses amounts overall financial situation payable chairman board members corporate executive committee respect remuneration committee makes reviews current reporting year based performance final decision individual base pay paid aforementioned objectives chairman board directors members time remuneration committee also decides corporate executive committee form bonuses awarded ie cash payments remuneration members board andor longterm blocked nonvoting equity securities andor blocked shares bonuses variable bonuses annually awarded individual stocksettled stock appreciation rights contributions value creation business year ssars variable meant incentive strive outstanding ssars entitle holders benefit financially results create new business opportunities increase value roches nonvoting equity bonus amounts linked group divisional securities grant date exercise date core profits sales growth constant exchange rates ssars granted vest together three operating profit capital charge opac based years exercised within seven years core operating profit core earnings per share grant date unexercised ssars lapse without nonvoting equity security nes growth constant compensation since fair value ssars exchange rates product development pipeline diversity calculated grant date using trinomial employees managers environmental goals model american options details see ssars corporate executive committee restricted stock units rsus allocated individually remuneration restricted stock units rsus committees discretion addition around remuneration component corporate employees received ssars executive committee replaced awarding corresponding psps see therefore performance share plan psp variable longterm incentive programmes corporate psp established periods three executive committee comprise psp awards years based threeyear comparison ssars approximately total shareholder return tsr peer structure lti simplified comparison companies see footnote competitors companys longterm performance mirrored share price respective year psp consists three tsr shall reflected strongly overlapping performance cycles new cycle corporate executive committees remuneration starting beginning year cycle finishing end year indirect benefits three overlapping performance cycles psp shown ceo roche group psp psp chairman respectively members psp closed december see corporate executive committee additionally received indirect benefits payments pension funds mgb stiftung der f hoffmannla roche ag fr plans key performance metric award mitarbeitergewinnbeteiligung als ergn zung der tsr calculated threemonth moving beruflichen vorsorge ie employee profitsharing average rate start end foundation supplementing occupational pension performance cycle payment psp benefits insurances roche connect payments determined board directors annual foreign tax obligation tax consulting services basis acting upon recommendations annual expense allowances shown remuneration committee individual members corporate executive committee received payments since psp awards remuneration component schooling costs children reserved corporate executive committee enlarged corporate executive committee whilst previous years members senior psp historical performance management participated psp since award originally targeted nes longterm incentive programmes previous psp participants comprise ssars rsus see approximately remuneration report roche weighting fixedvariable remuneration components target percentage total remuneration chairman board directors corporate executive committee including ceo roche group fixed variable ratio variable remuneration components relative fixed base pay corporate executive committee ratio variable remuneration components bonuses ssars psp relative value fixed base pay sti lti criteria bonus ssars psp individual target value minimum maximum performance criteria group objectives group divisional value development value development business performance individual determined performance determined performance objectives considering core profits sales plus value adjustment plus value adjustment growth constant exchange rates dividends nes dividends nesbearer operating profit capital charge opac grant shares grant based core operating profit core earnings group performance tsr per share nonvoting equity security relation tsr performance nes growth constant exchange rates peer set tsr definition product development pipeline diversity see employees managers environmental goals split group objectives na b individual objectives na na applicable assessed consideration performance competitors macroeconomic development based annual base pay measured january first year cycle details please refer following sections remuneration report see also finance report note roche group consolidated financial statements related parties note financial statements roche holding ltd board executive shareholdings remuneration board directors resolution approval amount remuneration members remuneration chairman board board directors directors members board directors members board directors decided remuneration committees received remuneration additional compensation discretion taking account market comparisons form quarterly fixed cash payments shown remuneration members board remuneration form cash payments directors table board annually tracked market data directors activities roche paid legally required employers pay leading global pharmaceuticals contributions total chf swiss social companies see footnote major swiss security programmes providing retirement disability companies see footnote assisted unemployment benefits ahvivalv consultancy pwc members board directors beside legally required contributions separately stated previous year board chairman board directors directors separately submit total aggregate bonus chairman board directors basic remuneration board directors general meeting financial year excluding chairman remained unchanged retrospectively binding approval since maximum amounts total aggregate exception chairman board remuneration board directors period directors bonus form blocked shares ordinary general meeting dr severin schwan executive member ordinary general meeting tabled board members board directors previous year general meetings awarded shares nonvoting equity securities prospectively binding approval see ssars loans credits granted members board directors capacity member chugai international council cic chugai pharmaceutical co ltd andr hoffmann received honoraria amounting total usd chf advisory service genentech scientific review board prof dr richard p lifton received honoraria amounting total usd chf list members positions committee memberships chairmanships see detiduaremuneration report roche remuneration members board directors chf additional remuneration additional special total basic remuneration committee memberschairs remuneration remuneration ch franz chairman see total remuneration paid chairman board directors hoffmann vicechairman see j bell j brown p bulcke hauser since march rp lifton see oeri b poussot schwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff pr voser p baschera retired march total exception members presidium chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board prorated remuneration period march december prorated remuneration paid period january march additionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration detidua remuneration members board directors chf additional remuneration additional special total basic remuneration committee memberschairs remuneration remuneration ch franz chairman see total remuneration paid chairman board directors hoffmann vicechairman p baschera j bell j brown since march p bulcke rp lifton oeri b poussot schwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff since march pr voser julius retired march b weder di mauro retired march total exception members presidium chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board prorated remuneration period march december prorated remuneration paid period january march additionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration total remuneration paid chairman form bearer shares blocked years payable board directors april put shareholder binding vote chairman dr christoph franz received total ordinary annual general meeting agm remuneration shown remuneration committees bonus proposal adopted chairmans total remuneration contained late respect financial year total remuneration board directors detiduaremuneration report roche total remuneration paid board board remuneration subject approval directors annual general meeting calendar year members board directors received remuneration including submission chairmans total aggregate bonuses employer contribution social bonus binding vote annual general securities beneficial parts totalling chf meeting chf excluding additional employers remuneration chairman board contribution paid ahvivalv totalling directors includes bonus award chf chf chf form shares blocked years shown form part remuneration table section total remuneration paid chairman board directors board remuneration paid former members directors submit remuneration committees board directors bonus proposal adopted late chairman former member board directors dr franz b board dr christoph franz respect humer received fees amounting total financial year payable april excluding legally usd chf serving member required employers contributions ahvivalv board directors chugai international shareholder binding vote ordinary council cic chugai pharmaceutical co ltd annual general meeting former member board directors william burns received honoraria amounting total usd chf capacity member chugai international council cic chugai pharmaceutical co ltd additional remuneration paid detidua total remuneration paid chairman board directors chf base salary cash bonus subject approval annual general meeting pension fundsmgb insurancesannual expense allowances total form shares blocked years calculation number shares based share price date transfer april respectively approval agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm respectively ncluding employer contribution social securities beneficial parts gb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits additionally employer contribution ahvivalv chf chf paid form part remuneration detidua retrospective approvals chairmans total aggregate bonus chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv bonus award form shares blocked years calculation number shares based share price date transfer april april april respectively approval agm agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm agm respectively submission boards total aggregate dr severin schwans remuneration shown future remuneration binding shareholder vote receives function ceo roche group board directors proposes member corporate executive committee ordinary agm approve board remuneration totalling included part corporate chf excluding legally executive committees total remuneration required employers contributions ahvivalv excluding bonuses period ending ordinary agm prospective approvals boards total aggregate future remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonuses reconciliation reported remuneration comparison ordinary agm ordinary shareholders approved remuneration agm actual remuneration amounted members board directors chf excluding legally required employers ordinary agm approved board remuneration contributions ahvivalv excluding bonuses totalling chf excluding legally required employers contributions ahviv alv excluding bonuses period ending ordinary agmremuneration report roche prospectively approved total remuneration members board directors comparison actual total payments made chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm maximum total remuneration approved agm actual total remuneration paid calculation end period within approved limit calculation end period yes yes excluding legally required employers contributions ahvivalv excluding bonuses security holdings related parties note directors andr hoffmann dr andreas oeri financial statements roche holding ltd members founders families closely significant shareholders addition associated belong contractually bound december december shareholder group pooled voting rights respectively members board directors end group held shares persons closely associated held roche issued shares detailed information shares nonvoting equity securities nes group found finance report note american depositary receipts adrs shown roche group consolidated financial statements table security holdings security holdings shares nes december december non voting nonvoting equity close relatives equity close relatives securities security securities security shares nes holdings others shares nes holdings others number number numbertype number number number numbertype number board directors ch franz hoffmann j bell j brown p bulcke hauser nes na na na na rp lifton adrs oeri b poussot schwan see security holdings see security holdings corporate executive committee corporate executive committee c suessmuth dyckerhoff pr voser retired board members retired march p baschera na na na na total nes adrs na applicable shares held shareholder group pooled voting rights listed jointly held close relative roches adr american depositary receipt listed otcqx wwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin us traded usd eight adrs represent one underlying nes remuneration corporate executive committee resolution approval remuneration committee board remuneration members corporate directors outlined remuneration executive committee decided decision process approval framework remuneration committees discretion taking account market comparisons members corporate executive committee received remuneration work previous year board shown amount remuneration directors separately submit total aggregate ceo roche group dr severin schwan bonuses corporate executive committee explained detail general meeting financial year retrospectively binding approval highest total remuneration paid dr severin schwan member corporate maximum amounts total aggregate executive committee remuneration corporate executive committee dr severin schwan executive member board period ordinary general meeting directors received remuneration primary ordinary general meeting function ceo roche group reflected tabled previous year general highest total remuneration paid member meetings prospectively binding approval see corporate executive committee see included total amount paid corporate amount remuneration members executive committee see total remuneration corporate executive committee paid members corporate executive general provisions assigning authority decisions committee corporate executive committee remuneration toremuneration report roche highest total remuneration paid dr severin schwan member corporate executive committee chf base salary ssars pension fundsmgb insurances roche connect bonus subject approval total aggregate bonuses corporate executive committee annual general meeting blocked nonvoting equity securitiesshares psp payments expense allowancefor tax consulting services total calculation value nonvoting equity securitiesshares consideration reduction value due blocking period years reduced market value including employer contribution social securities beneficial parts detailed calculation remuneration see annual report number ssars grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee number ssars grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee gb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits shares blocked years calculation number shares based share price date transfer april approval agm target number nonvoting equity securities psp nonvoting equity securities multiplied per nonvoting equity securities price averaged three months october december prior start performance cycle chf nonvoting equity security target number bearer shares psp bearer shares multiplied per bearer share price averaged three months october december prior start performance cycle chf bearer share includes annual expense allowance chf payments tax consulting services chf chf additionally employer contribution ahvivalv chf chf paid form part remuneration base pay members corporate executive committee base pay chf r diggelmann hippe g keller oday c wilbur total base pay including prorated remuneration period march december member corporate executive committee detidua detidua bonuses members corporate except dr severin schwan members executive committee corporate executive committee receive bonus remuneration committee board directors cash payment due april determined corporate executive committee dr severin schwan receive bonus members bonuses based performance form roche shares blocked years agreed objectives total aggregate bonus payment due april see amount bonuses brought forward binding vote annual general meeting bonus chf subject approval total aggregate bonuses corporate executive committee annual general meeting r diggelmann hippe g keller oday c wilbur total prorated remuneration period march december stocksettled stock appreciation rights fair value ssars calculated grant ssars members corporate date using trinomial model american options executive committee trinomial model effective method ssars shown ssars table valuation american call options considers entitle holders benefit financially possibility exercising option time prior increase value roches nonvoting equity maturity called american option compared securities nes grant date european option allows exercise exercise date strike price ssars maturity date terms multiyear plan closing price roche nes grant date ssars vest three years numbers ssars strike prices expiry dates grant date vested ssars exercised grant values ssars shown converted nes within seven years grant ssars table numbers ssars date unexercised ssars lapse without compensation calculated time issue entered values table pages information trinomial model american options please refer boyle phelim p lattice framework options pricing two state variables journal financial quantitative analysis volume issue mar rochecomtrinomialmodelpdf see strike prices table ssars detiduaremuneration report roche stocksettled stock appreciation rights ssars chf ssars ssars r diggelmann hippe g keller oday c wilbur total performance share plan psp roche securities perform better average members corporate executive committee peer set board directors elect increase since psp awards remuneration component nes bearer shares award maximum award reserved corporate executive committee double originallevel reserved target number enlarged corporate executive committee nes bearer shares according psp plan plus previous years members senior management value adjustment amount equivalent also participated performance share plan sum dividend paid vesting period attributable number nonvoting equity psp consists overlapping threeyear securities bearer shares individual performance cycles new cycle beginning award granted requires roche year thus three cycles progress securities perform well better psp psp psp peer set event investment whereas psp closed december roche securities underperforms average return none targeted bearer shares awarded delivered peer companies fewer nes psp per december none bearer shares awarded targeted nes awarded psp per december targeted nes nes reserved plan awarded historical psp performance members corporate executive committee see shown table board directors decide actual level provisions plan number nes bearer shares cash equivalent awards nonvoting equity securities nes bearer shares psp cycles close reserved participants cycle financial years respectively aim number securities actually awarded depend psp provide incentive participants whether extent investment roche achieve longterm value growth securities shares nes outperforms average return investment securities issued set end psp cycle based peer companies comparisons based threemonth average distributed dividends securities market prices dividend yields ie totalling chf billion chf billion total shareholder return tsr reduce effect chf billion chf billion shortterm market fluctuations security prices according terms plan participants averaged three months october december received none originally targeted bearer shares prior start performance cycle three months october december end cycle see footnote detidua restricted stock units members roche connect voluntary stock purchase plan corporate executive committee offering employees opportunity buy roche rsus see remuneration component nonvoting equity securities nes amount corporate executive committee replaced equal annual salary discount awarding corresponding psps therefore nes purchased plan subject variable longterm incentive programmes holding period four years switzerland corporate executive committee comprise psp awards ssars approximately addition members corporate executive committee received annual expense allowances indirect benefits members members payments foreign tax obligations corporate executive committee tax consulting services shown table employer contributions made social security schemes pension plans groupwide employee stock purchase plan roche connect respect members corporate executive committee shown indirect benefits employer contributions table employer contributions shown table detidua performance share plan psp fair value grant fair value grant per nonvoting per bearer share equity securities bearer share nes nes prices prices averaged averaged three three months fair value months october target number october target number december nonvoting december nonvoting prior fair value equity securities prior start equity securities target number start target number nes psp performance nes psp bearer shares performance cycle bearer shares cycle psp psp psp psp number value chf value chf number value chf value chf r diggelmann hippe ga keller oday c wilbur total calculation value nonvoting equity securitiesshares consideration reduction value due blocking period years reduced market value calculation value nonvoting equity securities consideration reduction value due blocking period years reduced market value remuneration report roche detidua detidua indirect benefits employer contributions chf pension payments pension payments funds annual taxtax funds annual taxtax mgb expense roche consulting mgb expense roche consulting insurances allowances connect services insurances allowances connect services r diggelmann hippe g keller oday c wilbur total including employer contribution social securities beneficial parts mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits remuneration loans members remuneration including bonuses employer corporate executive committee contribution social securities beneficial parts based contractual obligations roche totalling chf chf paid individual members corporate excluding additional employers contribution executive committee childrens schooling paid ahvivalv totalling chf costs totalling chf chf chf form part remuneration aforementioned additional payments included total remuneration members corporate additional remuneration executive committee mentioned payments paid current former members corporate executive committee loans credits granted members corporate executive committee executive remuneration subject approval annual general meeting maximum regular period notice members corporate executive committee months submission executive total aggregate changeofcontrol clauses bonuses binding vote annual employment contracts general meeting board directors proposes awarding members remuneration former members corporate executive committee bonuses corporate executive committee dr severin schwan form roche shares pensions totalling chf blocked years members chf paid former corporate corporate executive committee cash executive committee members payment see totalling chf respect financial year chf total remuneration paid members excluding legally required employers contributions corporate executive committee ahvivalv submit proposed total calendar year members amount ordinary annual general meeting corporate executive committee received agm binding vote detidua detidua detidua retrospective approvals members executive committees total aggregate bonuses chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv submission executive total future aggregate incentives ssars calculated grant value remuneration binding shareholder vote without considering reductions value due board directors proposes blocking periods applicable psp calculated ordinary agm approves remuneration time reservation nonvoting equity securities corporate executive committee totalling bearer shares taking account maximal chf excluding legally required potential double without considering reductions employers contributions ahvivalv value due blocking periods contributions excluding bonuses period ending pension benefits excluding legally required employers ordinary agm contributions ahvivalv well contributions expenses payments foreign tax obligations amount executive total future aggregate tax consulting services roche connect remuneration composed base pay longterm prospective approvals members executive committees total future aggregate remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonusesremuneration report roche reconciliation reported remuneration excluding bonuses period ending shareholders prospectively approved ordinary agm remuneration members corporate executive committee comparison ordinary agm ordinary agm approved remuneration ordinary agm remuneration amounted corporate executive committee totalling chf excluding legally required employers chf excluding legally required contributions ahvivalv excluding bonuses employers contributions ahvivalv psp assumption maximum value prospectively approved total remuneration members executive committee comparison actual total remuneration effected chf amount period amount period amount period agm agm agm agm agm agm maximum total remuneration prospectively approved agm total remuneration calculated end calculation end corresponding agmagm period period agm agm actual total remuneration realised corresponding agmagm period based calculation end calculation end actual amount calculated restrospectively end psp end end corresponding psp cycle cycle psp cycle within approved limit calculation end period yes yes additional amount paid new members corporate executive committee approval agm within approved total amount excluding legally required employers contributions ahvivalv excluding bonuses including assumption amount maximum possible award bearer sharesnonvoting equity securities corresponding psp cycle due award bearer shares psp cycle originally included calculation maximum possible award amount total remuneration period agm agm reduced chf clawback according regulations psp programme addition applicable statutory provisions originally targeted awarded nes shares roches longterm incentive plans include option shall lapse without compensation upon notice partially reclaim distributed compensation termination employment given reason result special circumstances clawback redundancy disability retirement employee voluntarily serves notice guidelines security holdings termination employment ssars see board directors decided ceo rsus see unvested date roche group cec members must acquire termination employment lapse immediately shares andor nes equivalent two annual base without compensation salaries ceo roche group since equivalent five annual base salaries one annual base salary upon termination employment result respectively end retain serious misconduct ssars rsus granted holdings long serve cec outstanding whether vested unvested shall lapse exception cristina wilbur joined immediately without compensation according corporate executive committee ssars plan rules serious misconduct must fulfil requirement end participant may include inter alia members corporate executive committee activity leading serious disciplinary action fulfil requirement repeated willful failure perform duties reasonably assigned roche security holdings violation law public regulation december december commission crime respectively members cec persons gross negligence willful misconduct closely associated held securities shown employment tables shares nonvoting equity securities engaging conduct bringing disgrace disrepute nes ssars restricted stock units rsus roche andor subsidiaries violation roches directives guidelines relating business conduct type security value acquired ceo roche group shares andor nes annual base salary members corporate executive committee shares andor nes annual base salaryremuneration report roche shares nonvoting equity securities nes december december close relatives close relatives shares nes security holdings shares nes security holdings number number numbertype number number numbertype corporate executive committee schwan r diggelmann hippe ga keller shares shares oday c wilbur total shares shares ssars number ssars held december corporate executive committee schwan r diggelmann hippe g keller oday ca wilbur total price chf market price per nes december chf expiry date grant value per ssar chf since trinomial model american call options v alues according corresponding annual reports restricted stock units rsus number rsus held december corporate executive committee schwan r diggelmann hippe since corporate executive committee g keller replaced award corresponding psps oday ca wilbur total grant value per rsu chf nes closing price grant date march rsus remuneration component committee remuneration committees corporate executive committee replaced discretion vested recipient award corresponding psps rsus contain three years thereafter resulting nonvoting rights receive nonvoting equity securities andor equity securities may remain blocked shares threeyear vesting period plus value years vesting blocking periods adjustment amount equivalent sum interests rsu recipients shall aligned dividend paid vesting period companys longterm success commitment attributable number nonvoting equity employees company shall increased securities individual award granted last time rsu awards rsus remuneration component continued allocated individually corporate executive around eligible roche employeesstatutory auditors report roche general meeting roche holding ltd basel audited accompanying remuneration audit involves performing procedures obtain audit report roche holding ltd year ended evidence disclosures made remuneration december audit limited report regard compensation loans credits information according articles accordance articles ordinance ordinance excessive compensation stock procedures selected depend auditors exchange listed companies ordinance contained judgement including assessment risks sections marked grey line including material misstatements remuneration report respective footnotes pages whether due fraud error audit also includes remuneration report evaluating reasonableness methods applied value components remuneration well assessing overall presentation remuneration responsibility board directors report board directors responsible preparation overall fair presentation believe audit evidence obtained remuneration report accordance swiss law sufficient appropriate provide basis ordinance board directors also opinion responsible designing remuneration system defining individual remuneration packages opinion opinion remuneration report year auditors responsibility ended december roche holding ltd responsibility express opinion complies swiss law articles accompanying remuneration report conducted ordinance audit accordance swiss auditing standards standards require comply ethical requirements plan perform audit obtain reasonable assurance whether remuneration report complies swiss law articles ordinance kpmg ag ian starkey marc ziegler licensed audit expert licensed audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved independent assurance report roche sustainability reporting corporate governance sustainability committee protection reporting guidelines published european roche holding ag basel chemical industry council cefic gri standards published october global reporting initiative engaged perform assurance procedures gri provide limited assurance aspects roche group internal corporate reporting manual sustainability reporting roche holding ag basel sustainability reporting guidanceeconomic performance consolidated subsidiaries roche included annual issued october report report roche materiality determination process corporate level based gri standards published october scope subject matter global reporting initiative gri limited assurance engagement focused following defined guidelines people contributions data information disclosed sustainability reporting key figures sustainability risks opportunities roche year ended december internally gathered collated aggregated management reporting processes respect sustainability reporting material aspects inherent limitations preparation safety security health environmental accuracy completeness sustainability indicators protection contributions people key figures well subject inherent limitations given nature methods related control environment relation data determining calculating estimating data aggregation key figures assurance report therefore read connection materiality determination process roche group level roches internal guidelines definitions procedures according requirements gri standards reporting sustainability performance disclosed report design sustainability risks opportunities roches responsibilities determination process based roche corporatelevel roche corporate governance sustainability committee activities disclosed paragraph risk responsible subject matter criteria well management report selection preparation presentation selected people key figures disclosed pages report information accordance criteria responsibility key figures including greenhouse gas emissions includes design implementation maintenance related scope scope resulting business travel internal control relevant reporting process free compressed air liquid nitrogen waste generated material misstatement whether due fraud error operations tables graphs pages report responsibility figures roche group level relation political responsibility form independent opinion based contributions disclosed pages report limited assurance procedures whether anything come attention indicate identified sustainability carried work data reported prior information selected contained report stated reporting periods performed work respect material respects accordance reporting criteria projections targets planned performed procedures accordance criteria international standard assurance engagements management reporting processes respect isae revised assurance engagements audits sustainability reporting key figures prepared reviews historical financial information standard roche based internal policies procedures set requires plan perform assurance engagement forth following obtain limited assurance identified sustainability roche group internal sustainability reporting guidelines information prepared material aspects accordance based responsible care health safety environmental roches internal policies proceduresindependent assurance report roche limited assurance engagement isae revised reviewing principles roche materiality process substantially less scope reasonable assurance providing definition development adherence engagement relation risk assessment procedures gris environmental social economic reporting including understanding internal control requirements addressing soundness identification procedures performed response assessed risks process determination impacted stakeholders peer consequently nature timing extent procedures competition review integration relevant regulatory gathering sufficient appropriate evidence deliberately limited requirements integration key organisational values relative reasonable assurance engagement therefore less objectives report prioritisation material aspects assurance obtained limited assurance engagement inspecting integration sustainability risks reasonable assurance engagement procedures opportunities group risk management process selected depend assurance practitioners judgement adherence internal guidelines assessment processes data consolidation independence quality control reviewing management ofand sustainability reporting complied independence ethical processes contributions people key figures requirements code ethics professional accountants assessing consolidation process data roche group level issued international ethics standards board accountants founded fundamental principles conducted work data outlined integrity objectivity professional competence due care subject matter defined believe evidence confidentiality professional behaviour obtained sufficient appropriate provide basis assurance conclusion firm applies international standard quality control accordingly maintains comprehensive system quality conclusion control including documented policies procedures regarding based work performed described report compliance ethical requirements professional standards identified roche sustainability reporting nothing applicable legal regulatory requirements come attention causing us believe material respects summary work performed roche group internal sustainability reporting guidelines assurance procedures included amongst others based gri standards well cefic guidelines following work applied review application roche group guidelines roche materiality determination process corporate reviewing application roche group internal level disclosed adhere principles guiding corporate sustainability contributions guidelines factors eg soundness stakeholder determination peer site visits management inquiry review relevance regulatory environment integration visiting selected sites roches pharmaceuticals key organisational values objectives defined diagnostics divisions us germany philippines gri standards south africa switzerland selection based design sustainability risks opportunities quantitative qualitative criteria determination process corporate level disclosed interviewing personnel responsible internal sustainability function designed reporting data collection sites visited internal reporting processes collect aggregate roche group level determine understanding people data functioning designed provide application roches internal sustainability guidelines appropriate basis disclosure assessment key figures internal reporting processes collect aggregate performing tests sample basis evidence supporting contributions data functioning designed provide selected contributions people key figures eg roche appropriate basis disclosure accident rate energy consumption greenhouse gas emissions sustainability information mentioned subject matter related energy consumption water waste contributions disclosed within sustainability reporting roche healthcare institutions patient organisations public policy annual report stated accordance bodies philanthropic organisations headcountfte data reporting criteria training hours concerning completeness accuracy adequacy consistency review documentation analysis relevant policies principles zurich february reviewing relevant documentation sample basis including pricewaterhousecoopers ag roche group sustainability policies management reporting structures documentation christophe bourgoin stephan hirschi published f hoffmannla roche ltd key dates group communications basel switzerland tel annual general meeting wwwrochecom march orderdownload publications firstquarter sales internet rochecompublications april email baselwarehouseservicesrochecom fax halfyear results july media relations tel nine months sales email rochemediarelationsrochecom october investor relations tel email investorrelationsrocheglobalcom corporate sustainability committee tel email corporatesustainabilityrochecomimprint roche cautionary statement regarding forwardlooking statement regarding earnings per share growth statements profit forecast interpreted annual report contains certain forwardlooking mean roches earnings earnings per share statements forwardlooking statements may subsequent period necessarily identified words believes expects match exceed historical published earnings anticipates projects intends seeks earnings per share roche estimates future similar expressions discussion among things strategy goals trademarks legally protected plans intentions various factors may cause actual results differ materially future links thirdparty pages provided convenience reflected forwardlooking statements contained express opinion content annual report among others pricing thirdparty pages expressly disclaim product initiatives competitors legislative liability thirdparty information use regulatory developments economic conditions delay inability obtaining regulatory approvals bringing products market fluctuations roche annual report published german currency exchange rates general financial market english conditions uncertainties discovery development marketing new products new reporting consists actual annual report uses existing products including without limitation finance report contains annual negative results clinical trials research projects financial statements consolidated financial unexpected side effects pipeline marketed statements regards content management products increased government pricing pressures report per articles incorporation consists interruptions production loss inability aforementioned reports exception obtain adequate protection intellectual property remuneration report rights litigation loss key executives employees adverse publicity printed nonchlorine bleached fsccertified paper news coveragedoing patients need nextwe believe urgent deliver medical solutions right noweven develop innovations future passionate transforming patients lives courageous decision action believe good business means better world come work day commit scientific rigour unassailable ethics access medical innovations today build better tomorrow proud many working one across functions across companies across world rochef hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom cover shows woman diagnosed cancer